

Desk by telephone or via SEND in the STNMAIL file.

=> s 14 and (ovarian or ovary or liver or hepat? or breast cancer or sarcoma or colon cancer or prostate cancer or endometrial cancer)

COMMAND INTERRUPTED

1 FILES SEARCHED.

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> d his

FILE 'HOME' ENTERED AT 17:29:31 ON 20 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:29:52 ON 20 DEC 2006

L1 STRUCTURE uploaded
L2 99066 S SSS L1 FULL

Bonnie

FILE 'CAPLUS, USPATFULL' ENTERED AT 17:30:30 ON 20 DEC 2006

L3 48931 S L2
L4 27791 S OV202 OR HTC OR CAOV OR MDA-MB OR HUVEC OR A431 OR HT 1080
L5 42 S L3 AND L4
L6 42 DUP REM L5 (0 DUPLICATES REMOVED)
L7 20020 S L4 AND (CANCER OR TUMOR OR TUMOUR OR CANCER? OR NEOPLAS? OR C
L8 14867 S L7 AND (OVARIAN OR OVARY OR LIVER OR HEPAT? OR BREAST CANCER
L9 307 S L8 AND (EDG OR LPA)
L10 302 DUP REM L9 (5 DUPLICATES REMOVED)
L11 302 FOCUS L10 1-
L12 175 S L11 AND PD <=2003
L13 175 FOCUS L12 1-

=> s 13 and (edg and lpa)

L14 4 L3 AND (EDG AND LPA)

=> s 13 and (cancer or tumour or tumor or sarcom? or neoplas? or cancer?)
L15 883 L3 AND (CANCER OR TUMOUR OR TUMOR OR SARCOM? OR NEOPLAS? OR
CANCER?)

=> s 15 and (ovary or ovarian or liver or hepat or breast or prostate or colon or
cervical or endometrial)

L16 344 L15 AND (OVARY OR OVARIAN OR LIVER OR HEPAT OR BREAST OR PROSTAT
E OR COLON OR CERVICAL OR ENDOMETRIAL)

=> dup rem 114

PROCESSING COMPLETED FOR L14

L17 4 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib abs 1-4

L17 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2005:131819 USPATFULL

TITLE: Methods of treating conditions associated with an
EDG-4 receptor

INVENTOR(S): Solow-Cordero, David, San Francisco, CA, UNITED STATES
Shankar, Geetha, Menlo Park, CA, UNITED STATES
Spencer, Juliet, San Mateo, CA, UNITED STATES
Gluchowski, Charles, Danville, CA, UNITED STATES

NUMBER KIND DATE

----- ----- -----

PATENT INFORMATION: US 2005113283 A1 20050526

APPLICATION INFO.: US 2003-390429 A1 20030314 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-347182, filed
on 21 Jan 2003, ABANDONED

Day : Wednesday

Date: 12/20/2006

Time: 15:20:34

**PALM INTRANET****Inventor Information for 10/760063**

Inventor Name	City	State/Country
SHANKAR, GEETHA	PALO ALTO	CALIFORNIA
SOLOW-CORDERO, DAVID	SAN FRANCISCO	CALIFORNIA
SPENCER, JULIET V.	SAN MATEO	CALIFORNIA
GLUCHOWSKI, CHARLES	DANVILLE	CALIFORNIA

[Appln Info](#) [Contents](#) [Petition Info](#) [Atty/Agent Info](#) [Continuity/Reexam](#) [Foreign](#)

Search Another: Application# or Patent#
 PCT / / or PG PUBS #
 Attorney Docket #
 Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1616BSK

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 22 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 23 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 24 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 25 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 27 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 28 DEC 18 CA/CAplus patent kind codes updated
NEWS 29 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 30 DEC 18 MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:34:31 ON 20 DEC 2006

FILE 'REGISTRY' ENTERED AT 15:38:20 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4
DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\edg-2.str

L1 STRUCTURE UPLOADED

```
=> s sss 11 full
FULL SEARCH INITIATED 15:38:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -          224 TO ITERATE
```


100.0% PROCESSED 224 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1

=> d 1-2


L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 339245-00-0 REGISTRY
ED Entered STN: 03 Jun 2001

CN Benzaldehyde, 3,4-dihydroxy-, [4-[(3,4-dimethylphenyl)amino]-6-[(4-nitrophenyl)amino]-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)
 MF C24 H22 N8 O4
 SR Chemical Library
 Supplier: Zelinsky Institute of Organic Chemistry
 LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 330630-42-7 REGISTRY
 ED Entered STN: 10 Apr 2001
 CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)
 MF C22 H18 N8 O4
 SR Chemical Library
 Supplier: Zelinsky Institute of Organic Chemistry
 LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

| | | |
|--------------------------|------------|---------|
| => file caplus uspatfull | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 170.74 | 172.00 |

FILE 'CAPLUS' ENTERED AT 15:39:12 ON 20 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:39:12 ON 20 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12

L3 5 L2

=> dup rem 13

PROCESSING COMPLETED FOR L3

L4 3 DUP REM L3 (2 DUPLICATES REMOVED)

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:409218 CAPLUS

DOCUMENT NUMBER: 142:441857

TITLE: Methods of treating conditions associated with an
edg-2 receptor

INVENTOR(S): Sollow-Cordero, David; Shankar, Geetha; Spencer,
Juliet; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.
Ser. No. 347,420, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 2005101518 | A1 | 20050512 | US 2003-390427 | 20030314 |
| PRIORITY APPLN. INFO.: | | | US 2002-350448P | P 20020118 |
| | | | US 2003-347420 | B2 20030117 |

OTHER SOURCE(S): MARPAT 142:441857

GI



AB In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with a modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:703122 CAPLUS

DOCUMENT NUMBER: 141:200233

TITLE: Methods of treating conditions associated with an
Edg-2 receptor

INVENTOR(S): Shankar, Geetha; Sollow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|------------|
| US 2004167132 | A1 | 20040826 | US 2004-760063 | 20040116 |
| | | | US 2003-440337P | P 20030116 |

PRIORITY APPLN. INFO.: MARPAT 141:200233

AB The invention provides a method for modulating an Edg-2 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Sолов-Кордера, Давид; Спенсер, Жюльет
V.; Глуховский, Чарльз

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2003062392 | A2 | 20030731 | WO 2003-US1881 | 20030121 |
| WO 2003062392 | A3 | 20050120 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2473740 | A1 | 20030731 | CA 2003-2473740 | 20030121 |
| AU 2003214873 | A1 | 20030902 | AU 2003-214873 | 20030121 |
| EP 1513522 | A2 | 20050316 | EP 2003-710713 | 20030121 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2005519915 | T | 20050707 | JP 2003-562260 | 20030121 |
| US 2005261298 | A1 | 20051124 | US 2003-390428 | 20030314 |
| PRIORITY APPLN. INFO.: | | | US 2002-350445P | P 20020118 |
| | | | US 2002-350446P | P 20020118 |
| | | | US 2002-350447P | P 20020118 |
| | | | US 2002-350448P | P 20020118 |
| | | | WO 2003-US1881 | W 20030121 |
| | | | US 2003-352579 | B2 20030127 |

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or

Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          22.41         194.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY        SESSION
CA SUBSCRIBER PRICE          -2.25         -2.25
```

FILE 'REGISTRY' ENTERED AT 15:48:49 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4
DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\edg-2-1.str
```

L5 STRUCTURE uploaded

```
=> s sss full 15
FULL SEARCH INITIATED 15:49:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        4 TO ITERATE
```

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L5

```
=>
Uploading C:\Program Files\Stnexp\Queries\edg-2-2.str
```

L7 STRUCTURE uploaded

=> s sss 17 full
FULL SEARCH INITIATED 15:50:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2769 TO ITERATE

100.0% PROCESSED 2769 ITERATIONS 896 ANSWERS
SEARCH TIME: 00.00.01

L8 896 SEA SSS FUL L7

=> file caplus uspatful
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 334.32 528.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -2.25

FILE 'CAPLUS' ENTERED AT 15:50:40 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:50:40 ON 20 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 18
L9 30 L8

=> focus
PROCESSING COMPLETED FOR L9
L10 30 FOCUS L9 1-

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 26 DUP REM L10 (4 DUPLICATES REMOVED)

=> d ibib abs 1-26

L11 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:291604 CAPLUS
DOCUMENT NUMBER: 144:480885
TITLE: In Silico Discovery of β -Secretase Inhibitors
AUTHOR(S): Huang, Danzhi; Luethi, Urs; Kolb, Peter; Cecchini, Marco; Barberis, Alcide; Caflisch, Amedeo
CORPORATE SOURCE: Department of Biochemistry, University of Zuerich, Zurich, CH-8057, Switz.
SOURCE: Journal of the American Chemical Society (2006), 128(16), 5436-5443
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Alzheimer's disease, the most common amyloid-associated disorder, accounts for the majority of the dementia diagnosed after the age of 60. The cleavage of the β -amyloid precursor protein is initiated by β -secretase (BACE-1), a membrane-bound aspartic protease, which has emerged as an important but difficult protein target. Here, an in silico screening approach consisting of fragment-based docking, ligand conformational search by a genetic algorithm, and evaluation of free energy of binding was used to identify low-mol.-weight inhibitors of BACE-1. More than 300,000 small mols. were docked and about 15,000 prioritized according to a linear interaction energy model with evaluation of

solvation by continuum electrostatics. Eighty-eight compds. were tested in vitro, and 10 of them showed an IC₅₀ value lower than 100 μM in a BACE-1 enzymic assay. Interestingly, the 10 active compds. shared a triazine scaffold. Moreover, four of them were active in an assay with mammalian cells (EC₅₀ < 20 μM), indicating that they are cell-permeable. Therefore, these triazine derivs. are very promising lead candidates for BACE-1 inhibition. The discoveries of this series and two other series of nonpeptidic BACE-1 inhibitors demonstrate the usefulness of our in silico high-throughput screening approach.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:132164 CAPLUS

DOCUMENT NUMBER: 144:404124

TITLE: Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells

AUTHOR(S): Pipalia, Nina H.; Huang, Amy; Ralph, Harold; Rujoi, Madalina; Maxfield, Frederick R.

CORPORATE SOURCE: Department of Biochemistry, Weill Medical College of Cornell University, New York, NY, 10021, USA

SOURCE: Journal of Lipid Research (2006), 47(2), 284-301

CODEN: JLPRAW; ISSN: 0022-2275

PUBLISHER: American Society for Biochemistry and Molecular Biology, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Niemann-Pick disease type C (NPC) is an autosomal recessive genetic disorder manifested by abnormal accumulation of unesterified cholesterol and other lipids. We screened combinatorially synthesized chemical libraries to identify compds. that would partially revert cholesterol accumulation. Cultured CHO cells with NPC phenotypes (CT60 and CT43) were used for screening along with normal CHO cells as a control. We developed an automated microscopy assay based on imaging of filipin fluorescence for estimating cholesterol accumulation in lysosomal storage organelles. Our primary screen of 14,956 compds. identified 14 hit compds. that caused significant reduction in cellular cholesterol accumulation at 10 μM. We then screened a secondary library of 3,962 compds. selected based on chemical similarity to the initial hits and identified 7 compds. that demonstrated greater efficacy and lower toxicity than the original hits. These compds. are effective at concns. of 123 nM to 3 μM in reducing the cholesterol accumulation in cells with a NPC1 phenotype.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:453800 CAPLUS

DOCUMENT NUMBER: 143:7706

TITLE: Pyrazole and other heterocyclics preparation for treating conditions associated with an Edg-4 receptor

INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 347,182, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.

KIND


DATE

APPLICATION NO.

DATE

| | | | | |
|------------------------|----|----------|-----------------|-------------|
| US 2005113283 | A1 | 20050526 | US 2003-390429 | 20030314 |
| PRIORITY APPLN. INFO.: | | | US 2002-350445P | P 20020118 |
| | | | US 2003-438996P | P 20030110 |
| | | | US 2003-440328P | P 20030116 |
| | | | US 2003-440329P | P 20030116 |
| | | | US 2003-440331P | P 20030116 |
| | | | US 2003-440332P | P 20030116 |
| | | | US 2003-440334P | P 20030116 |
| | | | US 2003-440335P | P 20030116 |
| | | | US 2003-440345P | P 20030116 |
| | | | US 2003-440346P | P 20030116 |
| | | | US 2003-440347P | P 20030116 |
| | | | US 2003-347182 | B2 20030121 |

OTHER SOURCE(S) : MARPAT 143:7706
GI




AB The present invention provides a method of modulating an Edg-4 receptor mediated biol. activity in a cell. A cell expressing the Edg-4 receptor is contacted with a modulator of an Edg-4 receptor sufficient to modulate the Edg-4 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-4 receptor mediated biol. activity in a subject. E.g., I was prepared from Et 4,4,4-trifluoroacetoacetate and 5-phenyl-1H-pyrazol-3-ylamine. I and other derivs. were tested for inhibition of the Edg-4 receptor and other pharmacol. tests such as proliferation, IL-8 and VEGF assays.

L11 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2005:409218 CAPLUS.
 DOCUMENT NUMBER: 142:441857
 TITLE: Methods of treating conditions associated with an edg-2 receptor
 INVENTOR(S): Sollow-Cordero, David; Shankar, Geetha; Spencer, Juliet; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 347,420, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|-------|----------|-----------------|-------------|
| ----- | ----- | ----- | ----- | ----- |
| US 2005101518 | A1 | 20050512 | US 2003-390427 | 20030314 |
| PRIORITY APPLN. INFO.: | | | US 2002-350448P | P 20020118 |
| | | | US 2003-347420 | B2 20030117 |

OTHER SOURCE(S) : MARPAT 142:441857
GI



AB In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L11 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:703122 CAPLUS
 DOCUMENT NUMBER: 141:200233
 TITLE: Methods of treating conditions associated with an Edg-2 receptor
 INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| US 2004167132 | A1 | 20040826 | US 2004-760063 | 20040116 |
| PRIORITY APPLN. INFO.: | | | US 2003-440337P | P 20030116 |

OTHER SOURCE(S): MARPAT 141:200233


AB The invention provides a method for modulating an Edg-2 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L11 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1076613 CAPLUS
 DOCUMENT NUMBER: 142:32992
 TITLE: Triazine derivatives for promoting collagen accumulation and inhibiting collagen decrease
 INVENTOR(S): Takahashi, Junya; Azuma, Kiyoshi
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Sumitomo Pharmaceutical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|


JP 2004352684 A 20041216 JP 2003-154442 20030530
 PRIORITY APPLN. INFO.: OTHER SOURCE(S) : MARPAT 142:32992
 GI



AB Triazine derivs. (I; X = halogen, low alkyl and alkoxy, nitro, trifluoromethyl; Y, Z = low alkyl; m, n = 0-2) are claimed for promoting collagen accumulation and inhibiting collagen decrease by increasing type I collagen gene transcription and decreasing MMP-1 gene transcription for diagnosis and treatment of low collagen-associated diseases.

L11 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:580592 CAPLUS
 DOCUMENT NUMBER: 141:123659
 TITLE: Preparation of substituted 1,3,5-triazine derivatives as anti-Alzheimer's agents
 INVENTOR(S): Willems, Henriette
 PATENT ASSIGNEE(S): De Novo Pharmaceuticals Ltd, UK
 SOURCE: Brit. UK Pat. Appl., 10 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|-------------------|----------|-----------------|----------|
| GB 2397301 | A | 20040721 | GB 2003-805 | 20030114 |
| PRIORITY APPLN. INFO.: | | | GB 2003-805 | 20030114 |
| OTHER SOURCE(S) : | MARPAT 141:123659 | | | |
| GI | | | | |



AB Title compds. I [wherein R1 = aryl; R2, R3 = independently H, alkyl, (hetero)aryl, alkylheteroaryl, or R2R3 = heterocycloalkyl; R4 = aryl; R = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared (no data). I and their pharmaceutical compns. are useful for the treatment or prevention of Alzheimer's disease (no data).

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2004:175230 USPATFULL

TITLE: Ink jet printing composition comprising a dye containing hydrazine or hydrazide

INVENTOR(S): Wight, Paul, Manchester, UNITED KINGDOM
Patel, Prakash, Manchester, UNITED KINGDOM

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004134382 | A1 | 20040715 |
| | US 7141106 | B2 | 20061128 |
| APPLICATION INFO.: | US 2003-469309 | A1 | 20030829 (10) |
| | WO 2002-GB810 | | 20020227 |

| | NUMBER | DATE |
|-----------------------|--------------|----------|
| PRIORITY INFORMATION: | GB 2001-5321 | 20010303 |
| | GB 2001-5324 | 20010303 |
| | GB 2001-5325 | 20010303 |
| | GB 2001-5328 | 20010303 |
| | GB 2001-6007 | 20010312 |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

LINE COUNT: 1842

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising:

(a) a liquid medium; and

(b) a compound comprising one or more chromophoric groups and one or more hydrazine or hydrazide groups;

wherein the liquid medium comprises water and an organic solvent, an organic solvent free from water, or a low melting point solid.

The composition is useful for ink jet printing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2003062392 | A2 | 20030731 | WO 2003-US1881 | 20030121 |

| | | | |
|------------------------|--|----------|----------------------------|
| WO 2003062392 | A3 | 20050120 | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| CA 2473740 | A1 | 20030731 | CA 2003-2473740 |
| AU 2003214873 | A1 | 20030902 | AU 2003-214873 |
| EP 1513522 | A2 | 20050316 | EP 2003-710713 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | |
| JP 2005519915 | T | 20050707 | JP 2003-562260 |
| US 2005261298 | A1 | 20051124 | US 2003-390428 |
| PRIORITY APPLN. INFO.: | | | |
| | | | US 2002-350445P P 20020118 |
| | | | US 2002-350446P P 20020118 |
| | | | US 2002-350447P P 20020118 |
| | | | US 2002-350448P P 20020118 |
| | | | WO 2003-US1881 W 20030121 |
| | | | US 2003-352579 B2 20030127 |

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g.

4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

L11 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:311343 CAPLUS

DOCUMENT NUMBER: 142:48466

TITLE: Local structure is critical for superoxide dismutase activity in copper complexes: Relationship between EPR parameters, structure, and activity in some sterically hindered copper(II) bis(hydrazono-triazine) complexes

AUTHOR(S): Goodman, B. A.; Palivan, C. G.; Palivan, H.; Tomas, S.

CORPORATE SOURCE: Scottish Crop Research Institute, Dundee, UK

SOURCE: Applied Magnetic Resonance (2003), 25(1), 13-28

CODEN: APMREI; ISSN: 0937-9347

PUBLISHER: Springer-Verlag Wien

DOCUMENT TYPE: Journal

LANGUAGE: English

AB ESR (EPR) spectrometry and mol. mechanics force field calcns. have been performed on some sterically hindered copper(II) complexes with hydrazono-triazine ligands, in order to gain further insight into the relationship between their bonding, structures and biol. activity. As was the case with Cu(II) bis(hydrazono-triazine) complexes studied previously, the most stable configuration for all of the complexes involves coordination of two nitrogen and two oxygen atoms (2N2O) in a distorted tetragonal arrangement. With the present complexes, however, the superoxide radical scavenging activities were very low, a result which may be explained by their inability to form a (nearly) square planar structure, which facilitates the copper redox cycling during superoxide dismutation.


REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2002:6713 CAPLUS
 DOCUMENT NUMBER: 136:85833
 TITLE: Preparation of N-(diaminotriazinyl)arylaldehyde hydrazones and analogs as antiviral agents
 INVENTOR(S): Arenas, Jaime E.; Cload, Sharon T.; Fleming, Elizabeth S.; Xiang, Yi Bin
 PATENT ASSIGNEE(S): Scriptgen Pharmaceuticals, Inc., USA
 SOURCE: U.S., 114 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|----------|-----------------------------------|------------------------|
| -----
US 6335339 | B1 | 20020101 | US 1999-229703
US 1998-113656P | 19990113
P 19980113 |

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 136:85833
 GI



AB Title compds. [e.g., I; R1-R8 = H, (un)substituted alk(en)yl, -(hetero)aryl, etc.; R1R2,R3R4,R7R8 = atoms to complete a ring] were prepared. Preparation of select I (e.g., R1 = CH2Ph, R2 = R4 = R7 = H, R3 = CMe3, R8 = C6H4F-2) was described. Data for biol. activity of I were given.
 REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:696050 CAPLUS
 DOCUMENT NUMBER: 137:234000
 TITLE: Ink jet printing composition comprising dyes containing hydrazine or hydrazide groups
 INVENTOR(S): Patel, Prakash
 PATENT ASSIGNEE(S): Avecia Limited, UK; Wight, Paul
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| -----
WO 2002070609 | A1 | 20020912 | WO 2002-GB810 | 20020227 |
| WO 2002070609 | A8 | 20040408 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|----------------|----------|
| GB 2389588 | A | 20031217 | GB 2003-19749 | 20020227 |
| GB 2389588 | B | 20050323 | | |
| US 2004134382 | A1 | 20040715 | US 2003-469309 | 20030829 |
| US 7141106 | B2 | 20061128 | | |

PRIORITY APPLN. INFO.:

| | | |
|-----------------|---|----------|
| GB 2001-5321 | A | 20010303 |
| GB 2001-5324 | A | 20010303 |
| GB 2001-5325 | A | 20010303 |
| GB 2001-5328 | A | 20010303 |
| GB 2001-6007 | A | 20010312 |
| US 2001-304161P | P | 20010321 |
| US 2001-304162P | P | 20010321 |
| US 2001-304176P | P | 20010321 |
| US 2001-813300 | A | 20010321 |
| US 2001-505353P | P | 20010321 |
| WO 2002-GB810 | W | 20020227 |

AB An ink jet composition comprises (a) a liquid medium and (b) a dye comprising one

or more chromophoric groups and one or more hydrazine or hydrazide groups, wherein the liquid medium comprises water and an organic solvent, an organic solvent free from water, or a low m.p. solid. The ink colors are stable and the inks have good storage stability and application properties. In an example, C.I. Acid Red 34 is treated (1:1 mol) with cyanuric chloride and the remaining 2 Cl atoms in the product are condensed with

1-amino-2,3-propanediol and then H₂NNHCONH₂ to give a magenta dye.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2002:224430 USPATFULL

TITLE: FVIIa/TF activity inhibiting compounds

INVENTOR(S): Jakobsen, Palle, Vaerl.o slashed.se, DENMARK

Persson, Egon, Åkarp, SWEDEN

PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 6444434 B1 20020903

APPLICATION INFO.: US 2001-844828 20010427 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-616010, filed on 13

Jul 2000, now patented, Pat. No. US 6238878

Continuation of Ser. No. WO 2000-DK316, filed on 13 Jun 2000

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: DK 1999-840 19990614

DK 1999-910 19990625

DK 1999-1241 19990903

US 1999-139714P 19990617 (60)

US 1999-141416P 19990629 (60)

US 1999-152863P 19990908 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Leary, Louise N.

LEGAL REPRESENTATIVE: Green, Esq., Reza

NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 26 USPATFULL on STN
ACCESSION NUMBER: 2001:78905 USPATFULL
TITLE: FVIIa/TF activity inhibiting compounds
INVENTOR(S): Jakobsen, Palle, V.ae butted.rl.o slashed.se, Denmark
Persson, Egon, Åkarp, Sweden
PATENT ASSIGNEE(S): Novo Nordisk AIS, Bagsvaerd, Denmark (non-U.S.
corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6238878 | B1 | 20010529 |
| APPLICATION INFO.: | US 2000-616010 | | 20000713 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 2000-DK316, filed on 13 Jun 2000 | | |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | DK 1999-840 | 19990614 |
| | DK 1999-910 | 19990625 |
| | DK 1999-1241 | 19990903 |
| | US 1999-139714P | 19990617 (60) |
| | US 1999-141416P | 19990629 (60) |
| | US 1999-152863P | 19990908 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Green, Esq., Reza
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:900841 CAPLUS
DOCUMENT NUMBER: 134:37031
TITLE: FVIIa/TF activity inhibiting compounds
INVENTOR(S): Jakobsen, Palle; Persson, Egon
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2000077246 | A2 | 20001221 | WO 2000-DK316 | 20000613 |

WO 2000077246 A3 20010222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1192270 A2 20020403 EP 2000-934951 20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003530819 T 20031021 JP 2001-503687 20000613
US 6238878 B1 20010529 US 2000-616010 20000713
US 6444434 B1 20020903 US 2001-844828 20010427

PRIORITY APPLN. INFO.: DK 1999-840 A 19990614
US 1999-139714P P 19990617
DK 1999-910 A 19990625
US 1999-141416P P 19990629
DK 1999-1241 A 19990903
US 1999-152863P P 19990908
WO 2000-DK316 W 20000613
US 2000-616010 A1 20000713

AB The invention relates to compds. inhibiting the activation of FX to FXa by TF/FVIIa. The compds. are anticoagulants. The invention also relates to a method of identifying a drug candidate.

L11 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:200595 CAPLUS
DOCUMENT NUMBER: 132:356267
TITLE: Tailor-made derivatizing agents for carbonyl compounds using liquid chromatography
AUTHOR(S): Kempfer, C.; Potter, W.; Binding, N.; Klaning, H.; Witting, U.; Karst, U.
CORPORATE SOURCE: Wilhelm-Klemm-Str. 8, Abteilung Analytische Chemie, Westfälische Wilhelms-Universität Münster, Anorganisch-Chemisches Institut, Münster, D-48149, Germany
SOURCE: Analytica Chimica Acta (2000), 410(1-2), 47-64
CODEN: ACACAM; ISSN: 0003-2670
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new approach for the synthesis and application of tailor-made derivatizing agents for liquid chromatog. is presented. The s-triazine ring serves as the backbone for these substances. Synthesis was performed in three steps based on substitution reactions of cyanuric chloride. A chromophore or fluorophore, a reactive group and a 3rd moiety intended to modify the polarity of the derivatizing agent are coupled to cyanuric chloride. The three groups may be selected freely from mols. which carry functional groups which might be linked to cyanuric chloride. As an example, the synthesis and application of a resp. reagent for the determination of

aldehydes and ketones using HPLC with fluorescence detection is carried out. Baseline separation of the derivs. and low limits of detection ($1.5 + 10^{-9}$ mol/L for formaldehyde, $2.0 + 10^{-9}$ mol/L for acetaldehyde and $3.0 + 10^{-9}$ mol/L for p-tolualdehyde) were obtained with the new versatile reagent.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:464283 CAPLUS

DOCUMENT NUMBER: 131:111412
 TITLE: Triazine antiviral compounds
 INVENTOR(S): Arenas, Jaime E.; Cload, Sharon T.; Fleming, Elizabeth S.; Xiang, Yi Bin
 PATENT ASSIGNEE(S): Scriptgen Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 9936410 | A1 | 19990722 | WO 1999-US945 | 19990113 |
| W: CA, GD, HR, ID, IN, JP | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2318362 | A1 | 19990722 | CA 1999-2318362 | 19990113 |
| EP 1053230 | A1 | 20001122 | EP 1999-902309 | 19990113 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002509140 | T | 20020326 | JP 2000-540126 | 19990113 |
| PRIORITY APPLN. INFO.: | | | US 1998-6430 | A 19980113 |
| | | | WO 1999-US945 | W 19990113 |

OTHER SOURCE(S): MARPAT 131:111412
 AB Pharmaceutical formulations comprising 1,3,5-triazine derivs. are provided. The compds. and formulations of the invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivs. bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.


REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:653431 CAPLUS
 DOCUMENT NUMBER: 132:116597
 TITLE: Superoxide scavenger copper(II) complexes having bis(hydrazino-triazine) ligands: an EPR and MM+ study
 AUTHOR(S): Palivan, C. G.; Darmon, C. E.; Thomas, St.
 CORPORATE SOURCE: Faculty of Physics, Department of Atomic and Nuclear Physics, University of Bucharest, Bucharest-Magurele, Rom.
 SOURCE: Bulletin of Magnetic Resonance (1999), 19(1/4), 29-33
 CODEN: BUMRDT; ISSN: 0163-559X
 PUBLISHER: International Society of Magnetic Resonance
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB EPR spectrometry and mol. mechanics force-field calcns. were used to characterize the coordination around the metal ions in four superoxide scavenger Cu(II) complexes having bis(salicylhydrazino-triazine) ligands. The distorted N2O2 square planar arrangement around Cu as well as the presence of N4O2 coordination is proposed as an explanation for the difference between their superoxide dismutase (SOD) activity and those described in a previous study.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:134825 CAPLUS
 DOCUMENT NUMBER: 114:134825

TITLE: Complexation property for alkali metal salts of hydrazone-type bis-crown ethers
 AUTHOR(S): Lu, Guoyuan; Wang, Defeng; Shi, Xiaolin; Hu, Hongwen
 CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, Peop. Rep. China
 SOURCE: Wuji Huaxue Xuebao (1989), 5(4), 72-8
 CODEN: WHUXEO; ISSN: 1001-4861
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 GI



AB I ($E = N$, $E' = CH$, $R = H$, $n = 2$; $E = E' = N$, $R = NHPh$, Pr , $n = 2$; $E = NO_2$, $E' = CH$, $R = H$, $n = 2, 3$) were prepared by the reactions of the bishydrazines with 4'-formylbenzo-15-crown-5 and -benzo-18-crown-6 and characterized by elemental anal., IR, 1H NMR, and mass spectroscopy. The stoichiometry of the complexes formed by I with alkali metal cation was determined by electrocond. titration of the ligand with alkali metal tetraphenylborate solns. I containing benzo-15-crown-5 units formed 2:1 I:metal sandwich type complexes with K^+ , Rb^+ and Cs^+ . I containing benzo-18-crown-6 units only formed 2:1 complexes with Cs^+ . Extnts. were carried out from aqueous alkali metal picrates solution with I solution in $CHCl_3$ and extraction equilibrium consts. were evaluated. Their extractability and cation-selectivity are more effectively than the corresponding monocyclic crown ethers.

L11 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:85250 CAPLUS
 DOCUMENT NUMBER: 104:85250
 TITLE: Studies on 1,3,5-triazines as antibacterial agents
 AUTHOR(S): Patel, J. M.; Dave, M. P.; Thaker, K. A.
 CORPORATE SOURCE: Dep. Chem., Bhavnagar Univ., Bhavnagar, 364 002, India
 SOURCE: Journal of the Institution of Chemists (India) (1985), 57(3), 111-12
 CODEN: JOICA7; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Twenty-six title compds. (I; R1 = Ph; 2-Cl = C₆H₄, 2-MeOC₆H₄, 4-EtCO₂C₆H₄, α -naphthalenyl, etc. and R2 = H or Cl) were prepared, in several steps starting from the substitution reaction of p-anisidine [104-94-9] with cyanuric chloride [108-77-0], and tested for inhibitory activity against *Staphylococcus aureus* and *Escherichia coli* in vitro.

L11 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985:6429 CAPLUS

DOCUMENT NUMBER: 102:6429

TITLE: Synthesis of substituted 1,3,5-triazines as tuberculostatic agents

AUTHOR(S): Dave, M. P.; Patel, J. M.; Langalia, N. A.; Thaker, K. A.


CORPORATE SOURCE: Dep. Chem., Bhavnagar Univ., Bhavnagar, 364 002, India
SOURCE: Journal of the Indian Chemical Society (1984), 61(3), 237-8

DOCUMENT TYPE: CODEN: JICSAH; ISSN: 0019-4522
Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 102:6429

GI



I

AB A series of 2,4-bis(arylarnino)-6-(pyridine-4-carboxhydrazido/substituted benzhydrazido)-1,3,5-triazines has been synthesized and tested against *Mycobacterium tuberculosis* strain H27Rv. Some of them, e.g. I (R = o-, p-ClC₆H₄), have shown significant tuberculostatic activity.

L11 ANSWER 22 OF 26 USPATFULL on STN

ACCESSION NUMBER: 77:35798 USPATFULL

TITLE: Triazine derivatives as stabilizers for organic materials

INVENTOR(S): Hofer, Kurt, Munchenstein, Switzerland

Tscheulin, Guenther, Riehen, Switzerland

PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 4033957 19770705

APPLICATION INFO.: US 1974-529024 19741203 (5)

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: CH 1973-17269 19731210

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Rush, Raymond V.

ASSISTANT EXAMINER: Tovar, Jose

LEGAL REPRESENTATIVE: Sharkin, Gerald D., Vila, Richard E., Borovian, Joseph J.

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

LINE COUNT: 379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Triazine derivatives of formula ##STR1## in which R._{sub.1} is a tertiary alkyl radical,

R._{sub.2} is hydrogen or a substituent, e.g. alkyl,

n is 0 or an integer,

R._{sub.3} is --NH-- or --O--CH._{sub.3}--.sub.m

Wherein m is an integer,

X is --O--, --S-- or --NR._{sub.6}--,

wherein R._{sub.6} is hydrogen or a substituent, e.g. alkyl or phenyl,

R._{sub.4} is one of the radicals signified by R._{sub.6}, or, when X is --NH--, a radical of formula ##STR2## R._{sub.1}, R._{sub.2}, n and R._{sub.3} being as indicated above, OR R._{sub.4}, R._{sub.6} and the common nitrogen atom, and optionally a further hetero atom, form a saturated 5- or 6-membered heterocyclic ring,

And R._{sub.5} is one of the radicals signified by --X--R._{sub.4}, or a substituent, e.g. alkyl,

Are useful for stabilizing organic materials, e.g. polypropylene, against the degradative effects of oxygen, heat and/or light.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 26 USPATFULL on STN

ACCESSION NUMBER: 76:27633 USPATFULL

TITLE: Aromatic heterocyclic hydrazide derivatives

INVENTOR(S): Hofer, Kurt, Munchenstein, Switzerland

Tscheulin, Guenther, Rieben, Switzerland

PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 3957765 19760518

APPLICATION INFO.: US 1974-456630 19740401 (5)

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: CH 1973-4917 19730405

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Curtis, Allen B.

LEGAL REPRESENTATIVE: Sharkin, Gerald D., Vila, Richard E., Borovian, Joseph J.

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

LINE COUNT: 321

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns novel aromatic heterocyclic hydrazide derivatives of the formula: ##SPC1##

Wherein A is a radical ##SPC2##

Wherein R._{sub.1} is tertiary alkyl and R._{sub.2} and R._{sub.3} are hydrogen or substituents, e.g. alkyl, R._{sub.4} is a group -X-R._{sub.14}.sub.' wherein X is a bridging function, e.g. O, and R._{sub.14} is a substituent, e.g. alkyl, a heterocyclic group

--N Z

wherein Z, with the nitrogen atom, forms a heterocyclic ring or a radical -NH-A, wherein A is as defined above, R._{sub.5} has inter alia one of the significances of R._{sub.4} and Y is -N= or -CH=, which are useful antioxidants, e.g. for stabilizing plastics material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:565032 CAPLUS
DOCUMENT NUMBER: 83:165032
TITLE: Compounds for stabilizing organic materials
INVENTOR(S): Hofer, Kurt; Tscheulin, Guenther
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| DE 2456735 | A1 | 19750612 | DE 1974-2456735 | 19741130 |
| CH 582231 | A5 | 19761130 | CH 1973-17269 | 19731210 |
| SE 7415066 | A | 19750611 | SE 1974-15066 | 19741202 |
| US 4033957 | A | 19770705 | US 1974-529024 | 19741203 |
| FR 2253745 | A1 | 19750704 | FR 1974-39796 | 19741205 |
| FR 2253745 | B1 | 19780623 | | |
| NL 7415919 | A | 19750612 | NL 1974-15919 | 19741206 |
| BE 823135 | A1 | 19750609 | BE 1974-151319 | 19741209 |
| JP 50088081 | A | 19750715 | JP 1974-140597 | 19741209 |
| ES 432714 | A1 | 19770216 | ES 1974-432714 | 19741209 |
| GB 1492770 | A | 19771123 | GB 1974-53222 | 19741209 |
| AT 7409793 | A | 19781015 | AT 1974-9793 | 19741209 |
| ES 451576 | A1 | 19780101 | ES 1976-451576 | 19760916 |
| PRIORITY APPLN. INFO.: | | | CH 1973-17269 | A 19731210 |
| | | | ES 1974-432714 | A3 19741209 |

GI For diagram(s), see printed CA Issue.

AB The compds. I (7) with R and R₁ = morpholino, piperidino, anilino, 2-methylanilino, and/or C₈H₁₇S and Z = NHCOCH₂CH₂, NHCO, or (CH₂)₃O₂C were prepared for use as stabilizers for compds. such as polypropylene (II) [9003-07-0]. Thus, a mixture of 2-hydrazino-4,6-dimorpholino-s-triazine [13017-47-5] 4, Et₃N 2, and dioxane 40 parts was treated with a solution of 4.4 parts 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl chloride [3062-64-4] and heated to 70° during 2 hr to prepare I (R = R₁ = morpholino, Z = NHCOCH₂CH₂) [56631-83-5], which was mixed (0.4%) with II as an antioxidant.

L11 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:99248 CAPLUS
DOCUMENT NUMBER: 82:99248
TITLE: [(Hydroxybenzylidene)hydrazino]triazines as
antioxidants
INVENTOR(S): Hofer, Kurt; Tscheulin, Guenther
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| DE 2416020 | A1 | 19741024 | DE 1974-2416020 | 19740402 |
| CH 567484 | A5 | 19751015 | CH 1973-4917 | 19730405 |
| US 3957765 | A | 19760518 | US 1974-456630 | 19740401 |
| GB 1468225 | A | 19770323 | GB 1974-14649 | 19740402 |
| BE 813260 | A1 | 19741003 | BE 1974-142818 | 19740403 |
| JP 49127987 | A | 19741207 | JP 1974-37751 | 19740403 |
| ES 424900 | A1 | 19761016 | ES 1974-424900 | 19740403 |
| FR 2224465 | A1 | 19741031 | FR 1974-12083 | 19740405 |
| IT 1015903 | B | 19770520 | IT 1974-50190 | 19740405 |
| PRIORITY APPLN. INFO.: | | | CH 1973-4917 | A 19730405 |

GI For diagram(s), see printed CA Issue.

AB Seven triazines I (R,R1 = e.g. arylamino or morpholino) were prepared and used in 0.4% addition as antioxidants for polypropylene [9003-07-0]. Thus, refluxing 2,4-dimorpholino-6-hydrazino-s-triazine [13017-47-5] and 4,3,5-HO(Me3C)2C6H2CHO [1620-98-0] in C6H6 for 12 hr gave 6-[(3,5-di-tert-butyl-4-hydroxybenzylidene)hydrazino]-2,4-dimorpholino-s-triazine [54589-58-1].

L11 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:114288 CAPLUS

DOCUMENT NUMBER: 76:114288

TITLE: Stabilizers for polyolefins

INVENTOR(S): Mueller, Helmut; Rosenberger, Siegfried; Schwarzenbach, Kurt

PATENT ASSIGNEE(S): Ciba-Geigy A.-G.

SOURCE: Ger. Offen., 68 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| DE 2129996 | A | 19711223 | DE 1971-2129996 | 19710616 |
| CH 534706 | A | 19730430 | CH 1970-9182 | 19700617 |
| CH 542257 | A | 19731115 | CH 1970-14666 | 19701002 |
| US 3850918 | A | 19741126 | US 1971-150757 | 19710607 |
| GB 1335602 | A | 19731031 | GB 1971-27846 | 19710614 |
| NL 7108285 | A | 19711221 | NL 1971-8285 | 19710616 |
| FR 2099116 | A5 | 19720310 | FR 1971-21873 | 19710616 |
| AT 304877 | B | 19730125 | AT 1971-5204 | 19710616 |
| ES 392294 | A1 | 19740616 | ES 1971-392294 | 19710616 |
| SU 381224 | A3 | 19730515 | SU 1971-1676386 | 19710617 |
| US 4007183 | A | 19770208 | US 1974-471408 | 19740520 |
| PRIORITY APPLN. INFO.: | | | CH 1970-9182 | A 19700617 |
| | | | CH 1970-14666 | A 19701002 |
| | | | SE 1970-9182 | A 19700617 |
| | | | SE 1970-14666 | A 19701002 |
| | | | US 1971-150757 | A3 19710607 |

AB Salicyloylhydrazino-s-triazines (I) [e.g., R = NPr₂, OPr, NMe₂ morpholino, NHMe, NHPr, NHC₈H₁₇, Pr, Ph, NHPH, NHNCOC₆H₄OH-2, N(CH₂CHEtBu)₂, dicyclohexylamino, NHC₁₈H₃₇, N(C₁₈H₃₇)₂], are prepared. Thus 2-(dipropylamino)-4,6-hydrazino-s-triazine [prepared from N₂H₄.HCl and 2-(dipropylamino)-4,6-dichloro-s-triazine] reacts with salicyloyl chloride in AcNMe₂ at room temperature with cooling to give 2-(dipropylamino)-4,6-bis(salicyloylhydrazino)-s-triazine (II) [34415-01-5]. I are excellent in polyolefins, (e.g., polypropylene [9003-07-0]) at 0.1-0.8 wt% as antioxidants, metal deactivators, and as color stabilizers, and in synergistic combinations with other stabilizers.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'CAPLUS, USPATFULL' AT 16:33:15 ON 20 DEC 2006

FILE 'CAPLUS' ENTERED AT 16:33:15 ON 20 DEC 2006

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:33:15 ON 20 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 153.37 | 682.10 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | -15.75 | -18.00 |

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 153.37 | 682.10 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | -15.75 | -18.00 |

FILE 'REGISTRY' ENTERED AT 16:33:25 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\edg-2-3.str

L12 STRUCTURE uploaded

=> s sss full l12
FULL SEARCH INITIATED 16:33:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 28156 TO ITERATE

100.0% PROCESSED 28156 ITERATIONS
SEARCH TIME: 00.00.01

4053 ANSWERS

L13 4053 SEA SSS FUL L12

=> file caplus uspatfull

COST IN U.S. DOLLARS

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 166.94 | 849.04 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 0.00 | -18.00 |

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 16:33:51 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:33:51 ON 20 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l13

L14 1909 L13

=> s l14 and (cancer or tumour or tumor or carcinoma or neoplas? or chemo? or cancer?)

L15 42 L14 AND (CANCER OR TUMOUR OR TUMOR OR CARCINOMA OR NEOPLAS? OR CHEMO? OR CANCER?)

=> dup rem l15

PROCESSING COMPLETED FOR L15

L16 41 DUP REM L15 (1 DUPLICATE REMOVED)

=> focus

PROCESSING COMPLETED FOR L16

L17 41 FOCUS L16 1-

=> d ibib abs 1-41 hitstr

L17 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:754380 CAPLUS

DOCUMENT NUMBER: 137:263071

TITLE: Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents

INVENTOR(S): Maillet, Patrick; Laoui, Abdelazize; Riou, Jean-Francois; Doerflinger, Gilles; Mergny, Jean-Louis; Hamy, Francois; Caulfield, Thomas

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2002076975 | A1 | 20021003 | WO 2002-FR1005 | 20020322 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 FR 2822468 A1 20020927 FR 2001-3916 20010323
 CA 2442012 A1 20021003 CA 2002-2442012 20020322
 EP 1373252 A1 20040102 EP 2002-720068 20020322
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004524349 T 20040812 JP 2002-576233 20020322
 US 2003087931 A1 20030508 US 2002-103883 20020325
 US 6887873 B2 20050503
 US 2005070571 A1 20050331 US 2004-993637 20041119
 PRIORITY APPLN. INFO.: FR 2001-3916 A 20010323
 GI FR 2001-10370 A 20010802
 US 2001-332009P P 20011123
 WO 2002-FR1005 W 20020322
 US 2002-103883 A3 20020325

OTHER SOURCE(S) : MARPAT 137:263071

GI



AB Title compds. I [A = XR1R2; X = N, O, S, alkyl radical; R1-2 = H, alkyl, heterocyclyl, etc.; R3-3' = H, alkyl, isoquinolinyl, quinolinyl, etc.; Ar1-2 = (un)substituted Ph, etc., and derivs. thereof] were prepared For instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-propanediamine in DMF with K2CO3 for 15 h at 100° to afford II. Examples include evaluation of all compds. of the invention for telomerase activity. I are anti-cancer agents.


IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-16-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-
(dimethylamino)ethyl]amino]triazine 462649-17-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-20-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-
methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine
462649-23-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine
462649-36-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-
methoxyethyl]amino]triazine 462649-37-2P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine
462649-39-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[N-(3-methylphenyl)-N-
ethylamino]methyl]amino]triazine 462649-41-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((benzyl)amino)triazine 462649-44-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(acetylamino)ethyl)amino)triazine 462649-45-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-
(benzyl)amino]ethyl]amino]triazine 462649-47-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-((methoxycarbonyl)amino)ethyl)amino)triazine
462649-48-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]triazine
462649-54-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[1-ethylpyrrolidin-2-
yl]methyl]amino]triazine 462649-55-4P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-
(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[1-methylpiperidin-4-yl]methyl]amino]triazine
462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[pyridin-2-yl]methyl]amino]triazine
462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine
462649-61-2P 462649-72-5P, 2-[[4-Amino-2-methylquinolin-
6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-3-
yl]methyl]amino]triazine 462649-73-6P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-
chlorobenzyl]amino]triazine 462649-80-5P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-
benzylpiperazinyl]methyl]amino]triazine 462649-86-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[morpholinyl]ethyl]amino]triazine 462649-87-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[isoquinolin-5-yl]methyl]amino]triazine 462649-89-4P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462649-90-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-91-8P,

2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-dimethylaminophenyl]methyl]amino]triazine
462649-96-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[piperidinyl]ethyl]amino]triazine
462649-97-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[isopropylamino]ethyl]amino]triazine
462650-53-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine 462650-55-1P
462650-62-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(acetylamino)ethyl]amino]triazine 462650-68-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-70-0P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine
462650-77-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-78-8P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-79-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine 462650-82-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,3-dihydroxypropan-2-yl]amino]triazine 462650-83-5P
462650-84-6P 462650-85-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,2-dihydroxyethyl]amino]triazine 462650-88-0P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-morpholinoethyl]amino]triazine
462650-89-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-piperidinylethyl]amino]triazine 462651-00-9P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine
462651-01-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[[4-isopropylpiperazinyl]carbonyl]methyl]amino]triazine 462651-06-5P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-[2-methylpiperidinyl]propyl]amino]triazine 462651-08-7P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[5-(piperidinyl)pentyl]amino]triazine
462651-10-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(imidazolyl)ethyl]amino]triazine 462652-84-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)


RN 462649-12-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 CAPLUS


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-36-1 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-37-2 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 462649-38-3 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-39-4 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[{ethyl(3-methylphenyl)amino}methyl]- (9CI) (CA INDEX NAME)




RN 462649-41-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-42-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-44-1 CAPLUS

CN Acetamide, N-[2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-45-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-46-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''-[2-[(dimethylamino)ethyl](phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 CAPLUS

CN Carbamic acid, [2-[[4,6-bis[(4-amino-2-methyl-6-quinoliny)amino]-1,3,5-triazin-2-yl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''-[2-(bis(1-methylethyl)amino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-54-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-55-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-56-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 CAPLUS


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 462649-60-1 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-methoxyphenyl]methyl- (9CI) (CA INDEX NAME)




RN 462649-61-2 CAPLUS
 CN Ethanaminium, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462649-72-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-73-6 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-[2-(4-morpholinyl)ethyl] - (9CI) (CA INDEX NAME)




RN 462649-87-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-(5-isoquinolinylmethyl) - (9CI) (CA INDEX NAME)




RN 462649-89-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-[(4-methoxyphenyl)methyl] - (9CI) (CA INDEX NAME)




RN 462649-90-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-96-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-53-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(phenylmethyl)-1-piperazinyl]methyl- (9CI) (CA INDEX NAME)




RN 462650-55-1 CAPLUS

CN Ethanaminium, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)




● Cl⁻


RN 462650-62-0 CAPLUS
 CN Acetamide, N-[2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)




RN 462650-68-6 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-(2-methoxypropyl) - (9CI) (CA INDEX NAME)




RN 462650-69-7 CAPLUS
 CN 1-Butanol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]methyl] - (9CI) (CA INDEX NAME)




RN 462650-70-0 CAPLUS
CN Ethanol, 2-[[4,6-bis[(4-amino-2-methyl-6-quinoliny)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-77-7 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinoliny]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 462650-78-8 CAPLUS
CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinoliny]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 CAPLUS
CN Ethanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinoliny]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-82-4 CAPLUS

CN 1,3-Propanediol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-83-5 CAPLUS


CN 1,3-Propanediol, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-84-6 CAPLUS


CN 1,2-Ethanediol, 1-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 CAPLUS

CN 1,2-Ethanediol, 1-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-methoxyphenyl]methyl- (9CI) (CA INDEX NAME)




RN 462651-01-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl] - (9CI) (CA INDEX NAME)




RN 462651-05-4 CAPLUS

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl) - (9CI) (CA INDEX NAME)




RN 462651-06-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidinyl)propyl] - (9CI) (CA INDEX NAME)




RN 462651-08-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 462651-10-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 462652-84-2 CAPLUS

CN 1-Propanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:472151 CAPLUS

DOCUMENT NUMBER: 143:26644

TITLE: Preparation of triazine dimers for the treatment of autoimmune diseases

INVENTOR(S): Penney, Christopher; Zacharie, Boulos; Abbott, Shaun D.; Bienvenu, Jean-Francois; Cameron, Alan D.; Duceppe, Jean-Simon; Ezzitouni, Abdallah; Fortin, Daniel; Houde, Karine; Moreau, Nancie; Wilb, Nicole; Groulx, Brigitte; Gagnon, Lyne

PATENT ASSIGNEE(S): Prometic Biosciences Inc., Can.

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2005049607 | A1 | 20050602 | WO 2004-CA2003 | 20041122 |
| WO 2005049607 | B1 | 20050714 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004291186 | A1 | 20050602 | AU 2004-291186 | 20041122 |
| CA 2554635 | A1 | 20050602 | CA 2004-2554635 | 20041122 |
| EP 1687297 | A1 | 20060809 | EP 2004-818743 | 20041122 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| PRIORITY APPLN. INFO.: | | | US 2003-524021P | P 20031124 |
| | | | WO 2004-CA2003 | W 20041122 |

OTHER SOURCE(S): MARPAT 143:26644
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (CH₂)_n; n = 0-2; B = O, -CH(Ph)-, II, etc.; Y, Y' =


CH, N; C = (CH₂)_n, -CH(CH₃)-; X = NH, O, S; R₁, R₂, R₃, R₄ = H, alkenyl, hydroxyalkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, aromatic nucleophilic substitution of N,N'-ethylenediamine di[4-chloro-6-(3-N-1-tert-butoxycarbonylaminophenyl)amino-1,3,5-triazine], e.g., prepared from cyanuric chloride in 2 steps, with 2-(4-aminophenyl)ethylamine followed by treatment with HCl afforded compound III. In competitive protein A binding assays, the IC₅₀ value of compound III was 0.2 μM. Compds. I are claimed useful for the treatment of rheumatoid arthritis, inflammation, etc.

IT 852672-67-4P 852672-79-8P 852672-80-1P
 852672-81-2P 852672-83-4P 852672-84-5P
 852672-85-6P 852672-87-8P 852672-90-3P
 852672-95-8P 852672-98-1P 852673-04-2P
 852673-05-3P 852673-07-5P 852673-08-6P
 852673-12-2P 852673-13-3P 852673-17-7P
 852673-19-9P 852673-20-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazine dimers for treatment of autoimmune diseases)
 RN 852672-67-4 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N''-1,2-ethanediylbis[N'-[4-(2-aminoethyl)phenyl]-N''-phenyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-79-8 CAPLUS
 CN Acetamide, N-[2-[[4-[[2-[[4-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 852672-80-1 CAPLUS

CN Phenol, 4-[2-[[4-[[2-[[4-[(4-aminobutyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-81-2 CAPLUS

CN Ethanol, 2-[[4-[[2-[[4-[[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-83-4 CAPLUS
CN Ethanol, 2-[4-[(3-aminophenyl)amino]-6-[[2-[4-[(3-aminophenyl)amino]-6-[(2-(4-aminophenyl)ethyl)amino]-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-1,3,5-triazin-2-yl]amino] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-84-5 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N-[4-[2-[[4-[(2-aminoethyl)amino]-6-[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]phenyl]-N'-(3-aminophenyl)-N''-[2-(4-aminophenyl)ethyl] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-85-6 CAPLUS

CN Phenol, 4-[2-[[4-[[2-[[4-[(2-hydroxyethyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-87-8 CAPLUS
CN Phenol, 4-[2-[[4-[[2-[[4-[(2-aminoethyl)amino]-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-90-3 CAPLUS
CN Phenol, 4-[2-[[4-[[2-[[4-[(3-aminopropyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 852672-95-8 CAPLUS


CN Phenol, 4-[2-[[4-[[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)




RN 852672-98-1 CAPLUS

CN Phenol, 4,4'-(1,4-phenylenebis[imino[6-(phenylamino)-1,3,5-triazine-4,2-diyl]imino-2,1-ethanediyl])bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852673-04-2 CAPLUS

CN Ethanol, 2-[[4-[[5-[[4-[[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-methylphenyl]methyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852673-05-3 CAPLUS

CN Ethanol, 2-[[4-[[3-[[4-[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]methyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852673-07-5 CAPLUS

CN Phenol, 4-[2-[[4-[[2-[[4-[2-(4-hydroxyphenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852673-08-6 CAPLUS

CN Phenol, 4,4'-(1,3-phenylenebis[imino[6-(phenylamino)-1,3,5-triazine-4,2-diyl]imino-2,1-ethanediyl])bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 852673-12-2 CAPLUS

CN Ethanol, 2-[4-[(3-aminophenyl)amino]-6-[[4-[[[4,6-bis[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂

RN 852673-13-3 CAPLUS

CN Ethanol, 2-[[4-[(3-aminophenyl)amino]-6-[[3-[[[4,6-bis[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂


RN 852673-17-7 CAPLUS

CN Ethanol, 2,2'-[1,4-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)




RN 852673-19-9 CAPLUS

CN Ethanol, 2,2'-[1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



RN 852673-20-2 CAPLUS

CN 1,3-Propanediol, 2,2'-[1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 41. CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1226082 CAPLUS

DOCUMENT NUMBER: 145:500066

TITLE: Triazine compounds and compositions thereof for the treatment of cancers

INVENTOR(S): Gagnon, Lyne; Zacharie, Boulos; Penney, Christopher

PATENT ASSIGNEE(S): Prometic Biosciences Inc., Can.

SOURCE: PCT Int. Appl., 46pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006122431 | A1 | 20061123 | WO 2006-CA832 | 20060519 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.:

US 2005-682374P

P 20050519

AB Compds. useful in the treatment of metastatic melanoma and other

cancers containing a triazine ring scaffold are described. These compds. may be classified into two groups: (1) two disubstituted triazine rings are covalently linked by an organic linker to each other and (2) one trisubstituted triazine ring.


IT 852673-17-7 852673-19-9 915154-46-0
915154-47-1 915154-51-7 915154-53-9
915154-54-0 915154-56-2 915154-58-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(triazine compds. and compns. thereof for treatment of cancers
)


RN 852673-17-7 CAPLUS

CN Ethanol, 2,2'-(1,4-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino])bis- (9CI) (CA INDEX NAME)



RN 852673-19-9 CAPLUS


CN Ethanol, 2,2'-(1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino])bis- (9CI) (CA INDEX NAME)




RN 915154-46-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 915154-47-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A

H₂N—




PAGE 1-B




RN 915154-51-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 915154-53-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 915154-54-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 915154-56-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 1-B



RN 915154-58-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 41 USPATFULL on STN
ACCESSION NUMBER: 2004:268339 USPATFULL
TITLE: Methods and compositions of novel triazine compounds
INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES

Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
 Saxena, Uday, Atlanta, GA, UNITED STATES
 Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
 Pal, Manojit, Hyderabad, INDIA
 Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
 Krishma Reddy, Velagala Venkata Rama Murali, Hyderabad,
 INDIA
 Sesila Sridevi, Bhatlapenumarthy, Hyderabad, INDIA
 Kumar, Potlapally Rajender, Hyderabad, INDIA
 Reddy, Gaddam Om, Hyderabad, INDIA


| | NUMBER | KIND | DATE |
|-----------------------|--|------|---------------|
| PATENT INFORMATION: | US 2004209882 | A1 | 20041021 |
| APPLICATION INFO.: | US 2003-400169 | A1 | 20030326 (10) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037,
ATLANTA, GA, 30357-0037 | | |
| NUMBER OF CLAIMS: | 19 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 86 Drawing Page(s) | | |
| LINE COUNT: | 12036 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676358-18-2P 676360-74-0P
 (preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)
 RN 676358-18-2 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N-(3-chloro-4-ethoxyphenyl)-N'-(1-ethyl-2-pyrrolidinyl)methyl]-N''-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676360-74-0 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N-[{(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:268338 USPATFULL
 TITLE: Methods and compositions of novel triazine compounds
 INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
 Alexander, Christopher W., Norcross, GA, UNITED STATES
 Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
 Saxena, Uday, Atlanta, GA, UNITED STATES
 Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
 Pal, Manojit, Hyderabad, INDIA
 Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
 Krishna Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
 Sridevi, Bhatlapenumarthy Sesha, Hyderabad, INDIA
 Kumar, Potlapally Rajender, Hyderabad, INDIA
 Reddy, Gaddam Om, Hyderabad, INDIA

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2004209881 | A1 | 20041021 |
| | US 7112587 | B2 | 20060926 |
| APPLICATION INFO.: | US 2003-400134 | A1 | 20030326 (10) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309 | | |

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 86 Drawing Page(s)

LINE COUNT: 9019

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 676360-74-0P

(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)

RN 676360-74-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N'-(

bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:268337 USPATFULL
TITLE: Methods and compositions of novel triazine compounds
INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Begumpet, INDIA
Pal, Manojit, Miyapur, INDIA
Reddy, Jangalgar Tirupathy, Miyapur, INDIA
Krlshna Reddy, Velagala Venkata Rama Murali,
Kukatpally, INDIA
Sridevi, Bhatlapenumarthy Sesha, Gandhinagar, INDIA
Kumar, Potlapally Rajender, Miyapur, INDIA
Reddy, Gaddam Om, Miyapur, INDIA

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 2004209880 A1 20041021
APPLICATION INFO.: US 2003-397968 A1 20030326 (10)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037,
ATLANTA, GA, 30357-0037

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 86 Drawing Page(s)

LINE COUNT: 10190

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676360-74-0P

(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)

RN 676360-74-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:696130 CAPLUS

DOCUMENT NUMBER: 133:256223

TITLE: A chemometric approach to understanding the bioelimination of anionic, water-soluble dyes by a biomass - Part 3: direct dyes

AUTHOR(S): Churchley, J. H.; Greaves, A. J.; Mutchings, M. G.; Phillips, D. A. S.; Taylor, J. A.

CORPORATE SOURCE: Severn Trent Water Ltd, Coventry, CV3 6PR, UK

SOURCE: Journal of the Society of Dyers and Colourists (2000), 116(9), 279-284

CODEN: JSDCAA; ISSN: 0037-9859

PUBLISHER: Society of Dyers and Colourists

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Using rapid and robust laboratory method for assessing the bioelimination of water-soluble dyes, the level of bioelimination of a series of direct dyes was determined and a chemometric anal. was conducted on the bioelimination results to correlate bioelimination with chemical structure. Bioelimination was 0-95% and correlated, for the majority of the direct dyes studied, with their size/charge ratio. The bioelimination of direct dyes was enhanced by large size/charge ratios, the presence of aromatic amino functions and extended azo (naphthalene) chromophores.

IT 295807-12-4


RL: REM (Removal or disposal); PROC (Process)
(chemometric approach to understanding bioelimination of anionic water-soluble direct dyes by biomass)

RN 295807-12-4 CAPLUS

CN 2-Naphthalenesulfonic acid, 7,7'-[6-[(2-hydroxyethyl)amino]-1,3,5-triazine-2,4-diyl]diimino]bis[4-hydroxy-3-[(4-methoxyphenyl)azo]-, disodium salt (9CI) (CA INDEX NAME)




●2 Na



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1972:81124 CAPLUS
 DOCUMENT NUMBER: 76:81124
 TITLE: Antitumor activities of fluorescent whitening agents of the stilbene class
 AUTHOR(S): Saito, Chiharu
 CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
 SOURCE: Oyo Yakuri (1970), 4(3), 521-4
 CODEN: OYYAA2; ISSN: 0300-8533
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 AB Tetrkasodium 4,4'-bis-[4-anilino-6-(p-sulfoanilino)-1,3,5-triazin-2-yl]amino]stilbene 2,2'-disulfonate (I) [34233-64-2], a stilbene [588-59-0] derivative used com. as a brightener, showed marked tumor inhibiting activity on solid forms of Ehrlich carcinoma, sarcoma 180, and carcinoma 63 in mice. Treatment before tumor transplant was superior to treatment after transplant. I had no effect on Ehrlich ascites carcinoma.
 IT 17958-73-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neoplasm inhibitor)
 RN 17958-73-5 CAPLUS
 CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyi)bis[5-[[4-[(2-hydroxyethyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

~ NH-CH₂-CH₂-OH

L17 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:69621 CAPLUS

DOCUMENT NUMBER: 134:256200

TITLE: A chemometric approach to understanding the bioelimination of anionic, water-soluble dyes by a biomass using empirical and semi-empirical molecular descriptors

AUTHOR(S): Greaves, A. J.; Churchley, J. H.; Hutchings, M. G.; Phillips, D. A. S.; Taylor, J. A.

CORPORATE SOURCE: Department of Colour Chemistry, University of Leeds, Leeds, LS2 9JT, UK

SOURCE: Water Research (2001), 35(5), 1225-1239
CODEN: WATRAG; ISSN: 0043-1354

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Single correlation and multiple linear regression analyses were applied to understand the bioelimination of 103 anionic, water-soluble dyes by a biomass at a wastewater treatment works. The chemometric approach highlighted that anionic, water-soluble dyes with larger mol. size/ionic charge ratios and containing more primary aromatic amines and unsulfonated naphthalene nuclei and fewer aliphatic alc. groups had superior levels of bioelimination.

IT 50925-42-3


RL: REM (Removal or disposal); PROC (Process)
(chemometric approach to understanding bioelimination of anionic water-soluble dyes by biomass using empirical and semi-empirical mol. descriptors)

RN 50925-42-3 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, 3,3'--[[6-[(2-hydroxyethyl)amino]-1,3,5-triazine-2,4-diyl]bis[imino(2-methyl-4,1-phenylene)azo]]bis-, tetrasodium salt (9CI) (CA INDEX NAME)



●4 Na



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1961:27935 CAPLUS
 DOCUMENT NUMBER: 55:27935
 ORIGINAL REFERENCE NO.: 55:5521e-i,5522a-i,5523a-i
 TITLE: Search for chemotherapeutic amidines. XVI.
 Amidinoanilino-1,3,5-triazines and related compounds
 AUTHOR(S): Ashley, J. N.; Berg, S. S.; MacDonald, R. D.
 CORPORATE SOURCE: May & Baker, Dagenham, UK
 SOURCE: Journal of the Chemical Society (1960) 4525-32
 CODEN: JCSOA9; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 52, 14559e. A series of amidinoanilino-1,3,5-triazines was prepared. Only 2,4-bis(p-amidinoanilino)-6-amino-1,3,5-triazine (I) had significant activity against Trypanosoma congoense. Attempts to improve this activity by various modifications to the structure gave less active products. 2-Amino-4,6-dichloro-1,3,5-triazine (II) was first prepared (0.5 molar scale) with Et₂O as the solvent for the cyanuric chloride; NH₃ was admitted (cooling bath at -20 to -25°) so that the internal temperature did not rise above -5°. II (66-79%) crystallized from C₆H₆ in white prisms, m. 234-5° (decomposition). The following method was preferred for preparation of larger amts. of II. Cyanuric chloride (553.5 g.) in 6 l. dry CHCl₃ treated 48 min. with NH₃ at a rate of 3 l./min. (below -12°) gave 638 g. II containing NH₄Cl; purification gave 367 g. pure II. 4,6-Dichloro-2-methylamino-1,3,5-triazine (82%), m. 160-1°, and 84% 4,6-dichloro-2-ethylamino-1,3,5-triazine, m. 106-7°, were prepared by a known method. 4,6-Dichloro-2-diethylamino-1,3,5-triazine (96%) m. 79-80°; 4,6-dichloro-2-methoxy-1,3,5-triazine (61%) m. 90-1°. II (165 g.) in 220 ml. anisole added in one portion to 472

g. p-aminobenzonitrile in 2400 ml. anisole at 100-110°, the bath temperature raised to 180-5°, refluxed 1.5 hrs., the mixture cooled, filtered, and the solid stirred 1 hr. at 20-5° with 10 l. 2N NaOH gave 325 g. 2-amino-4,6-bis(p-cyanoanilino)-1,3,5-triazine (III), yellow prisms, m. 339-41° (PhNO₂, C₅H₅N, or HCONMe₂). The following 1,3,5-triazines were prepared by the same method as for III: 70% 4,6-bis(p-cyanoanilino)-2-methylamino-, yellow, m. 281-2° (PhNO₂); 67% 4,6-bis(p-cyanoanilino)-2-ethylamino-, prisms, m. 249-51° (PhNO₂); 60% 4,6-bis(p-cyanoanilino)-2-diethylamino-, prisms, m. 205-7° (anisole); 60% 2-amino-4,6-bis(p-nitroanilino)-, green prisms, m. above 300° (PhNO₂); 64% 2-diethylamino-4,6-bis(p-nitroanilino)-, yellow needles, m. 316-17° (PhNO₂); 87% 4,6-bis(p-cyanoanilino)-2-methoxy-, white needles, m. above 300° (AcOH); and 58% 2-amino-4,6-bis(m-cyanoanilino)-1,3,5-triazine as the monoacetate, m. 240-2° (AcOH). p-Aminobenzonitrile (70.8 g.) in 250 ml. CHCl₃ added dropwise during 1 hr. to 55.35 g. cyanuric chloride in 500 ml. CHCl₃ at 15-20°, and the solid washed with 2N HCl gave 65 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine (IV). white rhombs, m. above 300° (Me₂CO, EtCOMe, or dioxane). Condensation carried out in Me₂CO or EtCOMe at 30-5°, 45-50°, or 55-60° gave IV; no 2-chloro-4,6-bis(p-cyanoanilino)-1,3,5-triazine was obtained. II (16.5 g.) added to 23.6 g. p-hydroxybenzonitrile in 8 g. NaOH and 125 ml. H₂O at 8-10°, the temperature allowed to rise during 2 hrs. to 25°, the mixture heated rapidly to 90-5°, kept 4 hrs. at this temperature, and filtered gave 23.5 g. 2-amino-4,6-bis(p-cyanophenoxy)-1,3,5-triazine, white plates, m. 288-9° (EtOCH₂CH₂OH). The following were prepared similarly: 72% 4,6-bis(p-cyanophenoxy)-2-diethylamino-1,3,5-triazine, white needles, m. 144-5° (alc.), and 57.5% 2-amino-4,6-bis(p-dimethylaminoanilino)-1,3,5-triazine, m. 283-6° (PhNO₂) (the di-HCl salt was deliquescent). The bis-(methosulfate), m. 274-6° (decomposition), was prepared from the base and Me₂SO₄ at 100° in PhNO₂. 4,6-Bis(p-cyanoanilino)-2-methoxy-1,3,5-triazine (3.4 g.) and 1 g. PhCH₂NH₂ in 100 ml. PhNO₂ heated 4-5 hrs. at 190° gave 1.3 g. 4,6-bis(p-cyanoanilino)-2-hydroxy-1,3,5-triazine as a crude product (insol. in alcs., hydrocarbons, AcOH, dioxane, anisole, PhCl, PhNO₂, and cresylic acid). 2-Amino-4,6-bis(p-nitroanilino)-1,3,5-triazine (18.3 g.) suspended in 183 ml. refluxing AcOH treated in one portion with 183 g. SnCl₂ in 183 ml. concentrated HCl, stirred 2 hrs. at 100°, cooled, the chloride filtered off and washed, and the red base filtered and treated with 2N HCl gave 9 g. 2-amino-4,6-bis(p-aminoanilino)-1,3,5-triazine-2HCl, white needles, m. above 300° (2N HCl). 4,6-Bis(p-aminoanilino)-2-diethylamino-1,3,5-triazine, obtained in 61% yield as pink needles, m. 196-7° (C₆H₆); di-HCl salt m. above 280°.

p-Aminobenzonitrile (23.6 g.) in 150 ml. Me₂CO containing 0.05 g. KI added to 13.3 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine in 600 ml. refluxing Me₂CO, the mixture refluxed 16 hrs., and the suspension filtered gave 14.1 g. 2,4,6-tris(p-cyanoanilino)-1,3,5-triazine, yellow, m. above 300° (PhNO₂). 4,6-Diaminoquinaldine (8.7 g.) in 200 ml. AcOH stirred 3 hrs. at 40-50° with 13.3 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine (V) in 200 ml. AcOH and the solid ground up with 2N NaOH gave 8.4 g. 4-(4-aminoquinaldin-6-ylamino)-2-chloro-6-(p-cyanoanilino)-1,3,5-triazine, yellow needles, m. above 300° (aqueous alc.). 2-Diethylaminoethylamine (11.6 g.) in 100 ml. Me₂CO added dropwise to a suspension of 13.3 g. V in 200 ml. Me₂CO, kept 3 hrs., evaporated, and the residual gum dissolved in 2N HCl gave (after basification) 10 g. 2-chloro-6-(p-cyanoanilino)-4-(2-diethylaminoethylamino)-1,3,5-triazine (VI), m. 143-5° (alc.). VI (16.1 g.) and 9.5 g. p-aminobenzonitrile in 120 ml. anisole refluxed 4 hrs. and the mixture filtered and ground with 2N NaOH gave 8.1 g. 4-(4-aminoquinaldin-6-ylamino)-2,6-bis(p-cyanoanilino)-1,3,5-triazine, brown prisms, m. above 300°. 2,6-Bis(p-cyanoanilino)-4-(2-diethylaminoethylamino)-1,3,5-triazine was prepared similarly (40% yield) from the corresponding 2-chloro compound as white prisms, m. 155-9° (alc.). V (26.6 g.) and 80 g. PhOH heated at 182-9°, NH₃ bubbled through for 6 hrs., the mass


ground with 500 ml. H₂O, and the product crystallized gave 18.3 g. 2,4-diamino-6-(p-cyanoanilino)-1,3,5-triazine, m. 282-3° (PhNO₂). Na dicyanamide (44.5 g.) in 250 ml. H₂O refluxed 6 hrs. with 129.8 g. p-aminobenzonitrile in 110 ml. concentrated HCl and 880 ml. H₂O and the precipitate collected, washed (2N NaOH), and crystallized gave 52.4 g. N₁,N₅-bis(p-cyanophenyl)biguanide (VII), m. 203-4° (slight decomposition). VII (23 g.) in 150 ml. 90% HCO₂H refluxed 3 hrs., cooled to 30°, and the product isolated gave 10.5 g. 2,4-bis(p-cyanoanilino)-1,3,5-triazine, prismatic needles, m. above 300° (PhNO₂). VII (20 g.), 60 ml. Me₂CO, and 0.9 ml. piperidine refluxed 2.5 hrs. gave 18.5 g. 2,4-bis(p-cyanoanilino)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine, m. 269-71° (decomposition) (MeOH). 2,4-Bis(p-cyanoanilino)-6-ethyl-1,6-dihydro-6-methyl-1,3,5-triazine, similarly prepared in 85% yield from EtMeCO as white needles, m. above 360°. 2-Diethylamino-4,6-bis(p-guanidinoanilino)-1,3,5-triazine, similarly prepared in 84% yield as white prisms, m. 174-5° (decomposition). III (500 g.) suspended in 1.5 l. dry alc. was ground 4 days in a ball-mill, the suspension saturated 12 hrs. at -15 to -20° with dry HCl, and the solid collected, washed, and dried; the yields of diimidoate (VIII) from 2 runs were 1400 g. and 1250 g. VIII stirred with dry alc. and added at 20-5° to liquid NH₃ in alc., the mixture stirred 6 hrs. at 50-5° and cooled, the solid filtered off and added (at 90°) to 20 l. 0.5N HCl, the mixture refluxed, filtered, treated with C, refiltered, cooled, and treated with HCl gave 804 g. and 606 g. crude 4,6-bis(p-amidinoanilino)-2-amino-1,3,5-triazine-3HCl.2H₂O (IX) from two runs. IX (50 g.) in hot MeOH cooled to 25°, treated with C, filtered, and treated with 300 ml. concentrated HCl gave 20-5 g. IX, m. above 360°. The amorphous diamidine base (80% yield), m. 195-8° (decomposition), was obtained by grinding the salt, VIII, with MeOH-2N NaOH; it did not crystallize; the diphosphate m. above 290°. The acid-insol. material obtained at the amination stage was essentially the corresponding 4,4'-dicarboxamide. The corresponding di-HCl salt, decomposing 255° (10.6 g.) ground with 2N NaOH and ice with 0.2 ml. Lissapol N gave 7 g. of the diimidoate. Treatment with aqueous alc. and NH₄Cl yielded 12% 2-amino-4,6-bis[p-(ethoxyiminomethyl)anilino]-1,3,5-triazine (together with the dicarboxamide). When ammonium isethionate was used in this conversion, only the dicarboxamide was obtained. A mixture of III (3.5 g.) and 3.5 g. ammonium benzenesulfonate heated 2.5 hrs. at 300° in a stream of NH₃ and cooled, the melt powdered and dissolved in 15 ml. hot H₂O, and the mixture filtered and cooled gave 2.3 g. melamine benzenesulfonate, m. above 300°. Treatment of a hot aqueous solution with NaOH gave melamine. Concentration of the aqueous liquors gave 0.2 g. p-aminobenzamide, m. 180-3°. Extraction of the initial aqueous mother liquor gave 0.1 g. p-aminobenzonitrile, m. 86-8°. The following p-[H₂N(HN:)C]C₆H₄XC:N.C{XC₆H₄[C(:NH)NH₂]p}:N. CR:N were prepared from the resp. nitriles by the Pinner method (X, R, alc. and solvent for imidoate preparation, time in days for imidoate preparation, amidine salt, crystallization solvent, % yield, and m.p. of product given): NH, NET₂, alc., 10, 2HCl, MeOH, 42, above 300°; O, NH₂, alc.-CHCl₃, 5, 2HCl, MeOH-Me₂CO, 33, 160° (decomposition); O, NET₂, alc.-CHCl₃, 5, 2HCl, MeOH-Me₂CO, 45, 255-7° (decomposition); NH, NHMe, alc., 14, 2HCl, aqueous NaCl, 53, 319-20° (decomposition); NH, NHET, alc., 21, 2HCl, aqueous NaCl, 55, 275-6° (decomposition); NH, NH(CH₂)₂NET₂, alc.-CHCl₃, 6, 3HCl, MeOH-Me₂CO, 42, 245-7° (decomposition); NH, 4-aminoquinaldin-6-ylamino, alc.-PhNO₂, 21, 3HCl, MeOH, 26.5, above 300°; NH, OMe, alc., 21, 2HCl, MeOH-Me₂CO, 41, above 300°; NH, p-amidinoanilino, HO(CH₂)₂OEt, 30, 4MeSO₃H, MeOH, 23.3, 212-14° (decomposition); NH, H, alc., 21, 2MeSO₃H, MeOH, 60, 306-8° (decomposition). N₁,N₅-Bis(p-amidinophenyl)biguanide was prepared by the general method (using 2-ethoxyethanol as the alc.); the imidoate preparation was kept 1 month; the diamidine-3HCl (13.2%) separated as white crystals, m. 355-6° (decomposition). 6-(p-Amidinoanilino)-2,4-diamino-1,3,5-triazine was prepared in

61% yield as the HCl salt after 4 weeks, m. 306-8° (decomposition). The imidoate preparation was kept 3 days only and a 62% yield of 2,4-bis(p-amidinoanilino)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine-3HCl separated as white prisms, m. above 300° (MeOH-Me₂CO). 2,4-Bis(p-amidinoanilino)-6-ethyl-1,6-dihydro-6-methyl-1,3,5-triazine-3HCl was similarly prepared (70% yield), prisms, m. above 300° (Me₂CO-MeOH). The following N-alkylamidines were obtained from the diimidoate-3HCl and the requisite amine in alc.: 56% 2-amino-4,6-bis[p-(N-methylamidino)]- (from MeOH-Et₂O) and 2-amino-4,6-bis[p-(N,N-dimethylamidino)anilino]-1,3,5-triazine-2HCl (from MeOH-Et₂O). 3-Dimethylaminopropylamine (20.4 g.) added to 16.5 g. II in 50 ml. H₂O, the mixture heated slowly to the b.p., a solution of 8 g. NaOH in 40 ml. H₂O added during 1 hr., and the mixture refluxed 2 hrs. and extracted with CHCl₃ gave a liquid, b.p. 200°, which solidified to a glass (25% yield). This base (5.8 g.) in 50 ml. EtOH treated with 5.7 g. tartaric acid in 25 ml. alc. gave the bis(H tartrate) of 2-amino-4,6-bis(3-dimethylaminopropylamino)-1,3,5-triazine, m. 78-80°. The base (7.2 g.) in 50 ml. Me₂CO treated with 3.5 ml. MeI gave the MeI salt. This product dissolved in H₂O and heated 5 min. with 1 mole diammonium 4,4'-diaminostilbene-2,2'-disulfonate gave the bisquaternary 4,4'-diaminostilbene-2,2'-disulfonate, pinkish powder, m. 283-5° (decomposition). 4,6-Bis(m-amidinoanilino)-2-amino-1,3,5-triazine was prepared by the standard method (using alc. as the solvent). The preparation kept 3 weeks afforded the di-HCl salt, m. above 300° (MeOH).

IT 109568-47-0P, Benzonitrile, 4,4'-(6-ethylamino-s-triazine-2,4-diyl)diimino]di- 110058-99-6P, Benzonitrile, 4,4'-(6-methylamino-s-triazine-2,4-diyl)diimino]di- 110061-41-1P, Benzimidine, 4,4'-(6-methylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride 111416-03-6P, Benzimidine, 4,4'-(6-ethylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride 115122-82-2P, Benzonitrile, 4,4'-(6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl)diimino]di- 118927-30-3P, Benzimidine, 4,4'-(6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl)diimino]di-, trihydrochloride
RL: PREP (Preparation)
(preparation of)


RN 109568-47-0 CAPLUS

CN Benzonitrile, 4,4'-(6-ethylamino-s-triazine-2,4-diyl)diimino]di- (6CI)
(CA INDEX NAME)




RN 110058-99-6 CAPLUS

CN Benzonitrile, 4,4'-(6-methylamino-s-triazine-2,4-diyl)diimino]di- (6CI)
(CA INDEX NAME)




RN 110061-41-1 CAPLUS

CN Benzimidine, 4,4'-(6-methylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride (6CI) (CA INDEX NAME)




● 2 HCl

RN 111416-03-6 CAPLUS
 CN Benzamidine, 4,4'-[6-(6-ethylamino-s-triazine-2,4-diyl)diimino]di-,
 dihydrochloride (6CI) (CA INDEX NAME)




● 2 HCl

RN 115122-82-2 CAPLUS
 CN Benzonitrile, 4,4'-[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-
 diyl]diimino di- (6CI) (CA INDEX NAME)



RN 118927-30-3 CAPLUS
 CN Benzamidine, 4,4'-[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-
 diyl]diimino di-, trihydrochloride (6CI) (CA INDEX NAME)




● 3 HCl

L17 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1969:27953 CAPLUS
 DOCUMENT NUMBER: 70:27953
 TITLE: Substituted melamines as chemosterilants of houseflies
 AUTHOR(S): LaBrecque, Germain C.; Fye, Richard L.; DeMilo, Albert B.; Borkovec, Alexej B.
 CORPORATE SOURCE: Entomol. Res. Div., Agr. Res. Serv., Gainesville, FL, USA
 SOURCE: Journal of Economic Entomology (1968), 61(6), 1621-32
 CODEN: JEENAI; ISSN: 0022-0493
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB One hundred ten substituted melamines were tested as chemosterilants against *Musca domestica*. Melamines that were sufficiently basic to form stable salts were tested as hydrochlorides. Fifty-five effectively inhibited hatch or pupation. The most effective inhibitors of hatch were tri- to hexasubstituted methylmelamines. Melamines without Me groups or methylmelamines containing large alkyl, aryl, or other bulky groups were ineffective against males. As a rule, compds. that affected hatch when both sexes were treated were also effective when only males were treated. Melamines that had 2 free amino groups and small cyclic substituents on the 3rd exocyclic N were generally without effect on hatch but they inhibited pupation of larvae produced by treated females. The inhibitors of pupation were ineffective in sterilizing males. All compds. were evaluated in 2 diets: sugar and fly food. The effects of the 2 foods and of the 2 forms of the compds. were often large, but only relatively uniform series of results were considered in structure-activity correlations.

IT 19860-91-4
 RL: BIOL (Biological study)
 (as insect sterilants)
 RN 19860-91-4 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N-butyl-N'-(4-methylphenyl)-N'''-phenyl- (9CI) (CA INDEX NAME)



L17 ANSWER 12 OF 41 USPATFULL on STN
 ACCESSION NUMBER: 2005:82123 USPATFULL
 TITLE: Chemical derivatives and their application as antitelomerase agents
 INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
 Laoui, Abdekazize, Bridgewater, NJ, UNITED STATES
 Riou, Jean-Francois, Reims, FRANCE
 Doerflinger, Gilles, Les Ulis, FRANCE
 Mergny, Jean-Louis, Villejuif, FRANCE
 Hamy, Francois, Illzach, FRANCE
 Caulfield, Thomas, Paris, FRANCE
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Antony, FRANCE (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|----------|
| PATENT INFORMATION: | US 2005070571 | A1 | 20050331 |

APPLICATION INFO.: US 2004-993637 A1 20041119 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2002-103883, filed on 25 Mar
2002, PENDING

| | NUMBER | DATE |
|--|--|---------------------------------------|
| PRIORITY INFORMATION: | FR 2001-3916
FR 2001-10370
US 2001-332009P | 20010323
20010802
20011123 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE
202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807 | |
| NUMBER OF CLAIMS: | 19 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2205 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

AB The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-16-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-
(dimethylamino)ethyl]amino]triazine 462649-17-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-20-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-
methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine
462649-23-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-
amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]tria-
zine 462649-36-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-
yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-
methoxyethyl]amino]triazine 462649-37-2P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine
462649-39-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[N-(3-methylphenyl)-N-
ethylamino]methyl]amino]triazine 462649-41-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((benzyl)amino)triazine 462649-44-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(acetylamino)ethyl)amino)triazine 462649-45-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-
(benzyl)amino]ethyl]amino]triazine 462649-47-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(methoxycarbonyl)amino)ethyl)amino)triazine
462649-48-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-
amino-2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]tr-
iazine 462649-54-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-
[[4-amino-2-methylquinolin-6-yl]amino]-6-[[1-ethylpyrrolidin-2-
yl]methyl]amino]triazine 462649-55-4P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-
(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P,


2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[1-methylpiperidin-4-yl]methyl]amino]triazine
462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-2-yl]methyl]amino]triazine 462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine 462649-61-2P 462649-72-5P,
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-3-yl]methyl]amino]triazine 462649-73-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-chlorobenzyl]amino]triazine 462649-80-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine
462649-86-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[morpholinyl]ethyl]amino]triazine 462649-87-2P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[isoquinolin-5-yl]methyl]amino]triazine 462649-89-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462649-90-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-91-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-dimethylaminophenyl]methyl]amino]triazine 462649-96-3P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[piperidinyl]ethyl]amino]triazine 462649-97-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[isopropylamino]ethyl]amino]triazine 462650-53-9P
, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine
462650-55-1P 462650-62-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(acetylamino)ethyl]amino]triazine 462650-68-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-70-0P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine
462650-77-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-78-8P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-79-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine 462650-82-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,3-dihydroxypropan-2-yl]amino]triazine
462650-83-5P 462650-84-6P 462650-85-7P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,2-dihydroxyethyl]amino]triazine
462650-88-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-morpholinoethyl]amino]triazine 462650-89-1P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-piperidinylethyl]amino]triazine
462651-00-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462651-01-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P

, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[[4-isopropylpiperazinyl]carbonyl]methyl]amino]triazine 462651-06-5P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-[2-methylpiperidinyl]propyl]amino]triazine 462651-08-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[5-(piperidinyl)pentyl]amino]triazine 462651-10-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(imidazolyl)ethyl]amino]triazine 462652-84-2P

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)


RN 462649-12-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, *N,N'*-bis(4-amino-2-methyl-6-quinolinyl)-*N*^{''}-(3-(dimethylamino)propyl) (9CI) (CA INDEX NAME)




RN 462649-36-1 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, *N,N'*-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-*N*^{''}-(2-methoxyethyl) (9CI) (CA INDEX NAME)



RN 462649-37-2 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, *N,N'*-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-*N*^{''}-(2-phenylethyl) (9CI) (CA INDEX NAME)




RN 462649-38-3 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, *N,N'*-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-*N*^{''}-(4-pyridinylmethyl) (9CI) (CA INDEX NAME)




RN 462649-39-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[ethyl(3-methylphenyl)amino]methyl] - (9CI) (CA INDEX NAME)




RN 462649-41-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(dimethylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 462649-42-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(phenylmethyl) - (9CI) (CA INDEX NAME)




RN 462649-44-1 USPATFULL

CN Acetamide, N-[2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-45-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-46-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-[2-[(2-(dimethylamino)ethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 USPATFULL


CN Carbamic acid, [2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'-(2-[bis(1-methylethyl)amino]ethyl)- (9CI) (CA INDEX NAME)




RN 462649-54-3 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'-(1-ethyl-2-pyrrolidinyl)methyl)- (9CI) (CA INDEX NAME)



RN 462649-55-4 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 462649-56-5 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-60-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 462649-61-2 USPATFULL


CN Ethanaminium, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462649-72-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-73-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-87-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(5-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-89-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(4-methoxyphenyl)methyl- (9CI) (CA INDEX NAME)




RN 462649-90-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[4-(dimethylamino)phenyl]methyl- (9CI) (CA INDEX NAME)




RN 462649-96-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-53-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinoliny]-N''-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 462650-55-1 USPATFULL


CN Ethanaminium, 2-[{[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino}-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462650-62-0 USPATFULL

CN Acetamide, N-[2-[{[4-(dimethylamino)-2-methyl-6-quinolinyl]amino}-1,3,5-triazin-2-yl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 462650-68-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-69-7 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-70-0 USPATFULL

CN Ethanol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-77-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-78-8 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 USPATFULL

CN Ethanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-82-4 USPATFULL

CN 1,3-Propanediol, 2-[(4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-83-5 USPATFULL


CN 1,3-Propanediol, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-84-6 USPATFULL


CN 1,2-Ethanediol, 1-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 USPATFULL

CN 1,2-Ethanediol, 1-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462651-01-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462651-05-4 USPATFULL

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME).




RN 462651-06-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462651-08-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 462651-10-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 462652-84-2 USPATFULL

CN 1-Propanol, 2-[[4,6-bis [[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2003:127716 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agent

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
Laoui, Abdelazize, Bridgewater, NJ, UNITED STATES
Riou, Jean-Francois, Reims, FRANCE
Doerflinger, Gilles, Les Ulis, FRANCE
Mergny, Jean-Louis, Villejuif, FRANCE
Hamy, Francois, Illzach, FRANCE
Caulfield, Thomas, Paris, FRANCE

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003087931 | A1 | 20030508 |
| | US 6887873 | B2 | 20050503 |
| APPLICATION INFO.: | US 2002-103883 | A1 | 20020325 (10) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | FR 2001-3916 | 20010323 |
| | FR 2001-10370 | 20010802 |
| | US 2001-332009P | 20011123 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | Finnegan, Henderson, Farabow,, Garrett & Dunner,
L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315 | |

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

LINE COUNT: 2835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel

anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-16-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-17-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-20-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-23-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-36-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-37-2P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-39-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[N-(3-methylphenyl)-N-ethylamino]methyl]amino]triazine 462649-41-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((benzyl)amino)triazine 462649-44-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(acetylamino)ethyl)amino)triazine 462649-45-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-(benzyl)amino]ethyl]amino]triazine 462649-47-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-((methoxycarbonyl)amino)ethyl)amino)triazine 462649-48-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]triazine 462649-54-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[1-ethylpyrrolidin-2-yl]methyl]amino]triazine 462649-55-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[1-methylpiperidin-4-yl]methyl]amino]triazine 462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-2-yl]methyl]amino]triazine 462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine 462649-61-2P 462649-72-5P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-3-yl]methyl]amino]triazine 462649-73-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-chlorobenzyl]amino]triazine 462649-80-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-benzylpiperazinyl]methyl]amino]triazine 462649-86-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[morpholinyl]ethyl]amino]triazine 462649-87-2P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-

amino-2-methylquinolin-6-yl]amino]-6-[[[isoquinolin-5-
yl]methyl]amino]triazine 462649-89-4P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-
methoxybenzyl]amino]triazine 462649-90-7P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-
methoxyethyl]amino]triazine 462649-91-8P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-
[[4-dimethylaminophenyl]methyl]amino]triazine 462649-96-3P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[piperidinyl]ethyl]amino]triazine 462649-97-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[isopropylamino]ethyl]amino]triazine 462650-53-9P
, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[4-benzylpiperazinyl]methyl]amino]triazine
462650-55-1P 462650-62-0P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[2-(acetylamino)ethyl]amino]triazine 462650-68-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-70-0P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-
amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine
462650-77-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-
methylethyl]amino]triazine 462650-78-8P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
462650-79-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-
hydroxyethyl]amino]triazine 462650-82-4P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[1,3-dihydroxypropan-2-yl]amino]triazine
462650-83-5P 462650-84-6P 462650-85-7P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[1,2-dihydroxyethyl]amino]triazine
462650-88-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-
morpholinoethyl]amino]triazine 462650-89-1P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[2-piperidinylethyl]amino]triazine
462651-00-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[4-
methoxybenzyl]amino]triazine 462651-01-0P, 2-[[4-Dimethylamino-
2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P
, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[4-isopropylpiperazinyl]carbonyl]methyl]a-
minoltriazine 462651-06-5P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[3-[2-methylpiperidinyl]propyl]amino]triazine
462651-08-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[5-
(piperidinyl)pentyl]amino]triazine 462651-10-1P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[2-(imidazolyl)ethyl]amino]triazine
462652-84-2P
(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as
anti-telomerase agents)


RN 462649-12-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-
quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-36-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-37-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 462649-38-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-39-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[(ethyl(3-methylphenyl)amino)methyl]- (9CI) (CA INDEX NAME)




RN 462649-41-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[2-(dimethylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 462649-42-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(phenylmethyl) - (9CI) (CA INDEX NAME)




RN 462649-44-1 USPATFULL

CN Acetamide, N-[2-[(4,6-bis[(4-amino-2-methyl-6-quinoliny)amino]-1,3,5-triazin-2-yl)amino]ethyl] - (9CI) (CA INDEX NAME)




RN 462649-45-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[2-(diethylamino)ethyl] - (9CI) (CA INDEX NAME)




RN 462649-46-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(dimethylamino)ethyl](phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 USPATFULL

CN Carbamic acid, [2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[bis(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-54-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-55-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-56-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N'''[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-60-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 462649-61-2 USPATFULL


CN Ethanaminium, 2-[[4,6-bis[(4-amino-2-methyl-6-quinoliny)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462649-72-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-73-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny)-N''-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-87-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(5-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-89-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-90-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-(dimethylamino)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-96-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-53-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(phenylmethyl)-1-piperazinylmethyl]- (9CI) (CA INDEX NAME)



RN 462650-55-1 USPATFULL


CN Ethanaminium, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462650-62-0 USPATFULL

CN Acetamide, N-[2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyllamino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-68-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyll-N'''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-69-7 USPATFULL


CN 1-Butanol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyllamino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-70-0 USPATFULL
CN Ethanol, 2-[[4,6-bis[(4-amino-2-methyl-6-quinoliny)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-77-7 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinoliny]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 462650-78-8 USPATFULL
CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinoliny]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 USPATFULL
CN Ethanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinoliny]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-82-4 USPATFULL

CN 1,3-Propanediol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-83-5 USPATFULL


CN 1,3-Propanediol, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-84-6 USPATFULL


CN 1,2-Ethanediol, 1-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 USPATFULL

CN 1,2-Ethanediol, 1-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462651-01-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462651-05-4 USPATFULL

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 462651-06-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462651-08-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidinyl)pentyl] - (9CI) (CA INDEX NAME)




RN 462651-10-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl] - (9CI) (CA INDEX NAME)



RN 462652-84-2 USPATFULL

CN 1-Propanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)



L17 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:964820 CAPLUS

DOCUMENT NUMBER: 141:395584

TITLE: Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation

INVENTOR(S): Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Reddy, Velagala Venkira Rama Murali Krishna; Sridevi, Bhatlapenumarphy Shesha; Kumar, Potlapally Rajender; Reddy, Gaddam Om Reddy Us Therapeutics, Inc., USA

PATENT ASSIGNEE(S): SOURCE: U.S. Pat. Appl. Publ., 433 pp., Cont.-in-part of U.S. Ser. No. 390,485.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 2004224950 | A1 | 20041111 | US 2003-400140 | 20030326 |
| US 7132423 | B2 | 20061107 | | |
| US 2004077648 | A1 | 20040422 | US 2003-390485 | 20030317 |
| JP 2006188533 | A | 20060720 | JP 2006-79816 | 20060322 |
| US 2006258641 | A1 | 20061116 | US 2006-441326 | 20060525 |
| PRIORITY APPLN. INFO.: | | | US 2001-324147P | P 20010921 |
| | | | US 2002-253388 | B1 20020923 |
| | | | US 2003-390485 | A2 20030317 |
| | | | JP 2004-538153 | A3 20030326 |
| | | | US 2003-400140 | A1 20030326 |

OTHER SOURCE(S): MARPAT 141:395584

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention relates to methods and compns. comprising compds. I or II [R1 = H, alkyl, cycloalkyl, etc.; G = NR1, O; J = CH, N; n = 0-3; X1 = o-R1, m-R1, m-OR1, m-OCF3, etc.; X2 = o-R1, p-R1, p-OR1, p-OCF3, etc.; X3 = o-R1, m-R1, p-R1, o-OR1, p-OR1; or X2 and X3 together is a fused benzene, pyridine, dioxane, tetrahydropyran ring; AY, DY = OR1, F, Cl, Br, I, tetrahydroquinolin-1-yl, etc.; or A, B = O, NR1; and Y = R1, (CHR1)qR1, (CHR1)qCF3, etc.; q = 0-3] that treat pathophysiol. conditions arising from inflammatory responses. Over 100 synthetic examples described synthesis of compds. I and II and their intermediates. E.g., a multi-step synthesis of the triazine III, starting from cyanuric chloride, is given. In particular, the present invention is directed to compds. that inhibit

or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compds. that inhibit smooth muscle cell (SMC) proliferation. Many of the compds. I and II inhibited SMC proliferation by greater than 70%. Also, the most effective compds. I and II showed an 80% decrease in IL-6 secretion in test for AGE-induced inflammatory response determination. In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

IT 676358-18-2P 676360-74-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)


RN 676358-18-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(3-chloro-4-ethoxyphenyl)-N'-(1-ethyl-2-pyrrolidinyl)methyl]-N''-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676360-74-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-[{(1-ethyl-2-pyrrolidinyl)methyl]methyl]-N'',N'''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 41 USPATFULL on STN
 ACCESSION NUMBER: 2003:296926 USPATFULL
 TITLE: Chemical derivatives and their application as antitelomerase agent
 INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
 Riou, Jean-Fran.cedilla.ois, Paris, FRANCE

Mergny, Jean-Louis, Villejuif, FRANCE
 Laoui, Abdelazize, Nogent sur Marne, FRANCE
 Lavelle, Fran.cedilla.ois, Paris, FRANCE
 Petitgenet, Odile, Paris, FRANCE
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Atony, FRANCE (non-U.S.
 corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6645964 | B1 | 20031111 |
| APPLICATION INFO.: | US 2000-722361 | | 20001128 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | FR 1999-15031 | 19991129 |
| | FR 2000-10561 | 20000811 |
| | US 2000-218059P | 20000713 (60) |
| | US 2000-176632P | 20000119 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Raymond, Richard L.

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1372

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 343875-95-6P 343876-01-7P

(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

RN 343875-95-6 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 343876-01-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-methyl-N'',N''-bis[2-methyl-4-(methylamino)-6-quinolinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L17 ANSWER 16 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:70738 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agent

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
Riou, Jean-Francois, Paris, FRANCE
Mergny, Jean-Louis, Villejuif, FRANCE
Laoui, Abdelazize, Nogent Sur Marne, FRANCE
Lavelle, Francois, Paris, FRANCE
Petitgenet, Odile, Paris, FRANCE

PATENT ASSIGNEE(S): Aventis Pharm S.A. (non-U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 2004053966 A1 20040318

APPLICATION INFO.: US 2003-658394 A1 20030910 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-722361, filed on 28 Nov 2000, GRANTED, Pat. No. US 6645964

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: FR 1999-15031 19991129

FR 2002-10561 20020811

US 2000-176632P 20000119 (60)

US 2000-218059P 20000713 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,
1300 I STREET, NW, WASHINGTON, DC, 20005

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

LINE COUNT: 1422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 343875-95-6P 343876-01-7P

(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

RN 343875-95-6 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N'''-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 343876-01-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-methyl-N''-bis[2-methyl-4-(methylamino)-6-quinolinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L17 ANSWER 17 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2002:303594 USPATFULL

TITLE: Asymmetric stilbene compounds

INVENTOR(S): Metzger, Georges, Moernach, FRANCE

Reinehr, Dieter, Kandern, GERMANY, FEDERAL REPUBLIC OF
Eckhardt, Claude, Riedisheim, FRANCE

Cuesta, Fabienne, Roppentzwiller, FRANCE

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 6482241 B1 20021119

APPLICATION INFO.: US 2000-657737 20000908 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-209940, filed on 11 Dec
1998, now patented, Pat. No. US 6143889

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: GB 1997-26365 19971213

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Gupta, Yogendra N.

ASSISTANT EXAMINER: Hamlin, Derrick G.

LEGAL REPRESENTATIVE: Mansfield, Kevin T.

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides, as a first aspect, an asymmetric compound having the formula: ##STR1##

in which M is hydrogen, an alkali metal atom, ammonium or a cation formed from an amine; Xa and Xb are the same or different and each is NH.sub.2; NH(C.sub.1-C.sub.4alkyl); NH(C.sub.2-C.sub.4alkoxyalkyl); N(C.sub.1-C.sub.4alkyl).sub.2; N(CH.sub.2CH.sub.2OH).sub.2; a group NH--Z--NR.sub.1R.sub.2 in which Z is C.sub.2-C.sub.14alkylene or optionally substituted arylene, and R.sub.1 and R.sub.2 are the same or different and each is C.sub.1-C.sub.12alkyl or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; an aminoacid residue; C.sub.1-C.sub.4alkoxy; hydroxy-substituted-C.sub.2-C.sub.4alkoxy; ##STR2##


and Ya and Yb are the same or different and each is a substituted amino group having both UVA and UVB-absorbing properties having the formula: ##STR3##

in which R.sub.3 is CN; SO.sub.2R.sub.5 in which R.sub.5 is, C.sub.1-C.sub.12alkyl, C.sub.1-C.sub.12alkoxy, NH.sub.2, NH(C.sub.1-C.sub.4alkyl), N(C.sub.1-C.sub.4alkyl).sub.2, N(CH.sub.2CH.sub.2OH).sub.2, C.sub.1-C.sub.4alkoxy or hydroxy-substituted-C.sub.2-C.sub.4alkoxy; COR.sub.5 in which R.sub.5 has its previous significance; COOM in which M has its previous significance or NHCOR.sub.5 in which R.sub.5 has its previous significance and in which R.sub.4 has the same significance as R.sub.3 or is H, OH, C.sub.1-C.sub.4alkyl or C.sub.1-C.sub.4alkoxy and one of Xa and Xb can be identical to one of Ya and Yb, provided that one of Xa and Xb is different from the other and/or one of Ya and Yb is different from the other.

The present invention also relates to a method of improving the sun protection factor (SPF) of textile fibre material, especially cotton, polyamide and wool, comprising treating them with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 31900-04-6P 200395-08-0P 203250-74-2P
226721-06-8P 226721-09-1P 226721-14-8P
226721-17-1P 226721-26-2P 226721-33-1P
(UV absorber; asym. triazinylaminostilbene compds. useful as sun protection agents applied to textiles)
RN 31900-04-6 USPATFULL
CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 200395-08-0 USPATFULL
CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A



●2 Na

PAGE 1-B


— CH₂— CH₂— OMe



RN 203250-74-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[4-(methylamino)-6-[(4-(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-06-8 USPATFULL


CN Benzoic acid, 4-[[4-[[2-[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-3-sulfophenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, trisodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●3 Na


PAGE 1-B



RN 226721-09-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-[2-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl], disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-14-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-[(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-17-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-(methylamino)-6-[[4-
[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-[[2-
[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-
sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-26-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-
[(aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-
yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-33-1 USPATFULL


CN Benzenesulfonic acid, 5-[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-(aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na

PAGE 1-B



L17 ANSWER 18 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2002:1233 USPATFULL

TITLE: Triazine antiviral compounds

INVENTOR(S): Arenas, Jaime E., Lexington, MA, United States
Cload, Sharon T., Cambridge, MA, United States

Fleming, Elizabeth S., Belmont, MA, United States
Xiang, Yi Bin, Acton, MA, United States
PATENT ASSIGNEE(S) : Scriptgen Pharmaceuticals, Inc., Waltham, MA, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6335339 | B1 | 20020101 |
| APPLICATION INFO.: | US 1999-229703 | | 19990113 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1998-113656P | 19980113 (60) |
| | US 1998-113656P | 19980113 (60) |

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Travers, Russell

LEGAL REPRESENTATIVE: Darby & Darby

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 265 Drawing Figure(s); 93 Drawing Page(s)

LINE COUNT: 1606

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 232937-01-8P 232937-02-9P 232937-06-3P
232937-55-2P 232937-59-6P

(preparation of N-(diaminotriazinyl)arylaldehyde hydrazones and analogs as antiviral agents)


RN 232937-01-8 USPATFULL

CN Phenol, 4-chloro-2-[[4-[(3,4-dimethylphenyl)amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 232937-02-9 USPATFULL

CN Phenol, 4-chloro-2-[[4-[(3,4-dimethylphenyl)amino]-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 232937-06-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(3,4-dimethylphenyl)-N'-(4-nitrophenyl)-N'''-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 232937-55-2 USPATFULL

CN Benzamide, 4-[[4-[(3,4-dimethylphenyl)amino]-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 232937-59-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(2,5-difluorophenyl)methyl]-N'-(3,4-dimethylphenyl)-N'''-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 19 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:150307 USPATFULL

TITLE: Asymmetric stilbene compounds

INVENTOR(S) : Metzger, Georges, Moernach, France
 Reinehr, Dieter, Kandern, Germany, Federal Republic of
 Eckhardt, Claude, Riedisheim, France
 Cuesta, Fabienne, Roppentzwiller, France
 PATENT ASSIGNEE(S) : Ciba Specialty Chemicals Corporation, Tarrytown, NY,
 United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6143889 | | 20001107 |
| APPLICATION INFO.: | US 1998-209940 | | 19981211 (9) |


| | NUMBER | DATE |
|-----------------------|---------------------|----------|
| PRIORITY INFORMATION: | GB 1997-26365 | 19971213 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Liott, Caroline D. | |
| LEGAL REPRESENTATIVE: | Mansfield, Kevin T. | |
| NUMBER OF CLAIMS: | 13 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 751 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Asymmetric compounds having the formula: in which M is hydrogen, an alkali metal atom, ammonium or a cation formed from an amine: Xa and Xb are the same or different and each is NH₂; NH(C₁₋₄alkyl); NH(C₂₋₄alkoxyalkyl); N(C₁₋₄alkyl)₂; N(CH₂CH₂OH).sub.2; a group NH-Z-NR₁R₂ in which Z is C₂₋₁₄alkylene or optionally substituted arylene, and R₁ and R₂ are the same or different and each is C₁₋₁₂alkyl or R₁ and R₂, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; an aminoacid residue; C₁₋₄alkoxy; hydroxy-substituted-C₁₋₄alkoxy; ##STR1## and Ya and Yb are the same or different and each is a substituted amino group having both UVA and UVB-absorbing properties having the formula: ##STR2## in which R₃ is CN; SO₂R₅ in which R₅ is C₁₋₁₂alkyl, C₁₋₁₂alkoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(CH₂CH₂OH).sub.2, C₁₋₄alkoxy or hydroxy-substituted-C₁₋₄alkoxy; COR₄. In which R₅ has its previous significance; COOM or NHCOR₅ and in which R₄ has the same meaning as R₃ or H, OH, C₁₋₄alkyl or C₁₋₄alkoxy and one of Xa and Xb can be identical to one of Ya and Yb, provided that one of Xa and Xb is different from the other and/or one of Ya and Yb is different from the other, and their use improve the sun protection factor (SPF) of textile fiber material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6P 200395-08-0P 203250-74-2P
 226721-06-8P 226721-09-1P 226721-14-8P
 226721-17-1P 226721-26-2P 226721-33-1P
 (UV absorber; asym. triazinylaminostilbene compds. useful as sun protection agents applied to textiles)
 RN 31900-04-6 USPATFULL
 CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)




●2 Na

RN 200395-08-0 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[4-acetylphenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)


PAGE 1-A



●2 Na

PAGE 1-B


—CH₂—CH₂—OMe



RN 203250-74-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-[(4-(methylamino)carbonyl)phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-06-8 USPATFULL


CN Benzoic acid, 4-[[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-3-sulfophenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, trisodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●3 Na


PAGE 1-B



RN 226721-09-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-[2-[[4-[(methylamino)carbonyl]phenyl]amino]-6-[[4-(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-14-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-17-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-[2-[[4-[(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 226721-26-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-[(4-aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B




RN 226721-33-1 USPATFULL

CN Benzenesulfonic acid, 5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[2-[[4-[(4-aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na



L17 ANSWER 20 OF 41 USPATFULL on STN

ACCESSION NUMBER: 96:96755 USPATFULL

TITLE: Dendritic amplifier molecules having multiple terminal

active groups stemming from a benzyl core group

INVENTOR(S): Keana, John F. W., Eugene, OR, United States

Martin, Vladimir, Eugene, OR, United States

Ralston, William H., St. Charles, MO, United States

PATENT ASSIGNEE(S): State of Oregon Acting by and Through the State Board
of Higher Education on Behalf of the University of
Oregon, Eugene, OR, United States (U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 5567411

19961022

APPLICATION INFO.: US 1994-316787

19940929 (8)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1993-133652, filed on 6 Oct 1993, now patented, Pat. No. US 5412148 which is a division of Ser. No. US 1992-887542, filed on 22 May 1992, now patented, Pat. No. US 5252317 which is a division of Ser. No. US 1989-403595, filed on 5 Sep 1989, now patented, Pat. No. US 5135737 which is a continuation-in-part of Ser. No. US 1986-928943, filed on 10 Nov 1986, now patented, Pat. No. US 4863717

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Higel, Floyd D.

LEGAL REPRESENTATIVE: Klarquist Sparkman Campbell Leigh & Winston, LLP

NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 2948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dendritic derivatives of 3,5-bis(aminomethyl)benzene and aminomethyl benzene core groups are disclosed. In each derivative, termed an "amplifier" because the dendritic structure on each molecule terminates with multiple termini to each of which an "active group" can be attached, the desired effect of the active group per mole is amplified compared to conventional compounds having only one active group per molecule. Amplifier molecules can include a targeting group permitting the molecules to preferentially attach to a particular anatomical or physiological situs. Active groups are any of various pharmacologically or therapeutically active moieties, including moieties useful for magnetic-resonance contrast enhancement. The dendritic structures comprise linkers and branch groups covalently bonded to each other in any of various structural combinations. The amplifiers can be prepared as a solution or mixture with a physiologically compatible carrier for administration to a warm-blooded animal subject. Also disclosed are methods for using the compounds in diagnosis and therapy, such as obtaining a magnetic resonance image of a subject.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 184177-05-7P


(preparation of dendritic amplifier mols. having multiple terminal active groups stemming from a benzyl core group as MRI contrast agents)

RN 184177-05-7 USPATFULL
CN Benzoic acid, 3,5-bis[[[4,6-bis[(4-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 21 OF 41 USPATFULL on STN
ACCESSION NUMBER: 2003:33159 USPATFULL
TITLE: Combinations of sunscreens
INVENTOR(S): Malpede, Alverio, Bergamo, ITALY
Zanchi, Giorgio, Bergamo, ITALY
PATENT ASSIGNEE(S): 3V Sigma S.p.A., Milan, ITALY (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6514485 | B1 | 20030204 |
| APPLICATION INFO.: | US 1999-475018 | | 19991230 (9) |

| | NUMBER | DATE |
|-----------------------|----------------|----------|
| PRIORITY INFORMATION: | IT 1999-BG1 | 19990111 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Dees, Jose' G. | |

ASSISTANT EXAMINER: George, Konata M.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Combinations of sunscreens comprising at least one specific anti uv-B filter with triazinoaniline structure and at least one specific anti UV-A filter selected from filters with benzoxazol substituted triazinoaniline structure and a long chain alkyl ester of a benzoxazolyl-aminophenyl-cyanoacrylic acid. Cosmetic and dermatological compositions containing them, optionally in combination with vitamins and/or other anti UV-A and anti UV-B filters.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205493-09-0

(sunscreens containing UV-A and UV-B filters)

RN 205493-09-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylethyl)-2-benzoxazolyl]phenyl]-N''-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




IT 288254-14-8P 288254-15-9P 288254-16-0P

(sunscreens containing UV-A and UV-B filters)

RN 288254-14-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(1,1-dimethylethyl)-N',N''-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Et

RN 288254-15-9 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylethyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)



RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 22 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:96330 USPATFULL

TITLE: Triazine derivatives and their use

INVENTOR(S) : Eckhardt, Claude, Riedisheim, France

Reinehr, Dieter, Kandern, Germany, Federal Republic of
Metzger, Georges, Moernach, France

Sauter, Georges, Reimach, France
Sauter, Hanspeter, Schopfheim, Germany, Federal
Republic of

PATENT ASSIGNEE(S) : Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:

US 5939379 19990817

APPLICATION INFO.:

US 1997-867110 19970602 (8)

NUMBER DATE

PRIORITY INFORMATION: GB 1996-17322 19960817
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lieberman, Paul
ASSISTANT EXAMINER: Petruncio, John M.
LEGAL REPRESENTATIVE: Mansfield, Kevin T.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1,10
LINE COUNT: 653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to new compounds which are useful as ultraviolet absorbing agents (UVAs) and as fluorescent whitening agents (FWAs), and to a method of improving the sun protection factor (SPF) of textile fibre material, especially cotton, polyamide and wool, treated with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 203250-74-2P 203250-76-4P

(preparation of triazine derivs. as fluorescent whitening agents and UV absorbers for increasing the sun protection factor of textile material)

RN 203250-74-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 203250-76-4 USPATFULL

CN Benzoic acid, 4,4'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-(methylamino)-1,3,5-triazine-4,2-diyl]imino]]bis[2-hydroxy-, tetrasodium salt (9CI) (CA INDEX NAME)



● 4 Na



L17 ANSWER 23 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:40138 USPATFULL

TITLE: Cosmetic and dermatological light protection formulations

INVENTOR(S): Hoop, Kerstin, Pinneberg, GERMANY, FEDERAL REPUBLIC OF
Lerg, Heike, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Mueller, Anja Sabine, Rumpel, GERMANY, FEDERAL REPUBLIC OFNissen, Bente, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Steinforth, Melanie, Hamburg, GERMANY, FEDERAL REPUBLIC OFSugar, Martin, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Beiersdorf AG (non-U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER KIND DATE

| PATENT INFORMATION: | NUMBER | KIND | DATE |
|---------------------|---------------|------|---------------|
| APPLICATION INFO.: | US 2006034785 | A1 | 20060216 |
| | US 2005-39376 | A1 | 20050119 (11) |

NUMBER DATE

| PRIORITY INFORMATION: | NUMBER | DATE |
|-----------------------|----------------|----------|
| | DE 2004-102004 | 20040119 |

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 1000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Light protective cosmetic or dermatological preparation, characterized in that it comprises (a) PEG-30 dipolyhydroxystearate, (b) 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, (c) at least one dibenzoylmethane derivative and (d) at least 2% by weight of titanium dioxide particles (based on the total weight of the preparation), the preparation being free from water-soluble UV-A filter substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, Uvasorb K2A

(cosmetic and dermatol. sunscreen formulations free of water-soluble UV-A filters)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 24 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:9579 USPATFULL

TITLE: Cosmetic and dermatological photoprotective formulations

INVENTOR(S): Doring, Thomas, Dormagen, GERMANY, FEDERAL REPUBLIC OF
Sugar, Martin, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Wolber, Rainer, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Wendel, Volker, Frankfurt/Main, GERMANY, FEDERAL REPUBLIC OF

REPUBLIC OF
Blatt, Thomas, Wedel, GERMANY, FEDERAL REPUBLIC OF
Mundt, Claudia, Bremen, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Batzer, Jan, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Dippe, Rixa, Hamburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

PATENT INFORMATION: US 2006008426 A1 20060112
APPLICATION INFO.: US 2005-87395 A1 20050323 (11)

| NUMBER | DATE |
|--------|------|
|--------|------|

PRIORITY INFORMATION: DE 2004-10200 20040323
DE 2004-10200 20040427

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

LINE COUNT: 1891

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetic or dermatological preparations which have a UVA balance of more than 15, and use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. compns. containing water-soluble sunscreens)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 25 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:318024 USPATFULL

TITLE: Emulsion concentrate containing water-soluble and oil-soluble polymers

INVENTOR(S): Pfeifer, Svenja, Hamburg, GERMANY, FEDERAL REPUBLIC OF Mundt, Claudia, Bremen, GERMANY, FEDERAL REPUBLIC OF

Daniels, Rolf, Salzgitter, GERMANY, FEDERAL REPUBLIC OF Beiersdorf AG (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2005276763 | A1 | 20051215 |
| APPLICATION INFO.: | US 2005-132821 | A1 | 20050519 (11) |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | DE 2004-1020040 | 20040519 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US | |
| NUMBER OF CLAIMS: | 23 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1715 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is the preparation and use of an emulsion concentrate obtainable by drying an oil-in-water emulsion comprising a

lipid phase, one or more oil-soluble polymers; an aqueous phase, one or more water-soluble polymers, one or more UV photoprotective filters and optionally further cosmetic or dermatological active ingredients, auxiliaries and additives, to produce a water content of from 0.1 to 20% by weight, based on the total weight of the dried preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, UVAsorb K2A

(cosmetic emulsion concentrate containing water-soluble and oil-soluble polymers)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N'''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 26 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:280500 USPATFULL

TITLE: Cosmetic concentrate

INVENTOR(S): Stiller, Sabine, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): BEIERSDORF AG, Hamburg, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005244443 A1 20051103

APPLICATION INFO.: US 2005-133295 A1 20050520 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2003-EP50845, filed on 18
Nov 2003, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: DE 2002-10254334 20021121

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE
PLACE, RESTON, VA, 20191, US

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

LINE COUNT: 1704

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for preparing an O/W emulsion concentrate. The process comprises subjecting an O/W emulsion comprising 20% to 95% by weight of one or more lipids, 0.5% to 80% by weight of microfine amphiphilic metal oxide particles, amphiphilic polymer particles, and/or modified polysaccharide particles and water to spray-drying and/or freeze-drying.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, UVAsorb K2A

(concentrated cosmetics and method for preparation)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 27 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:164657 USPATFULL

TITLE: Cosmetic or dermatological light protection formulation with a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF

Lerg, Heike, Hamburg, GERMANY, FEDERAL REPUBLIC OF Beiersdorf AG (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005142080 A1 20050630

APPLICATION INFO.: US 2004-871819 A1 20040618 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-EP14298, filed on 16 Dec 2002, UNKNOWN

NUMBER DATE

PRIORITY INFORMATION: DE 2001-10162841 20011220

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1

LINE COUNT: 1932

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light protection-active cosmetic or dermatological preparation comprising (a) at least one benzoxazole derivative, and (b) at least one oil component having a surface tension (σ) of less than 37 mN/m (at 25° C). The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the cosmetic or dermatological preparation to the skin. The invention is also a method of increasing the solubility of benzoxazole in a preparation comprising adding at least one oil component. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light protection formulations having a content of benzoxazol derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 28 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:56098 USPATFULL

TITLE: Cosmetic or dermatological light-protective formulation comprising a water-soluble UV filter substance and a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF Klette, Eckhard, Bad Odesloe, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005048009 A1 20050303

APPLICATION INFO.: US 7060257 B2 20060613
 RELATED APPLN. INFO.: US 2004-871840 A1 20040618 (10)
 Continuation of Ser. No. WO 2002-EP14296, filed on 16
 Dec 2002, UNKNOWN

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | DE 2001-10162840 | 20011220 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000 | |
| NUMBER OF CLAIMS: | 66 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1842 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation comprising (a) at least one water-soluble UV-filter substance and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one water-soluble UV-filter substance and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the cosmetic or dermatological preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, Uvasorb K2A

(cosmetic and dermatol. light-protective formulations comprising water-soluble UV-filter substances and benzoxazole derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

ACCESSION NUMBER: 2005:36883 USPATFULL
 TITLE: Cosmetic or dermatological light-protective formulation comprising a hydroxybenzophenone and a benzoxazole derivative
 INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
 Eitrich, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2005031556 | A1 | 20050210 |
| APPLICATION INFO.: | US 2004-871861 | A1 | 20040618 (10) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 2002-EP14391, filed on 17 Dec 2002, UNKNOWN | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | DE 2001-10162843 | 20011220 |
| | DE 2002-10249367 | 20021023 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000 | |
| NUMBER OF CLAIMS: | 50 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1827 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation, comprising (a) at least hydroxybenzophenone and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one hydroxybenzophenone of a specified chemical structure and at least one benzoxazole derivative. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising hydroxybenzophenones and benzoxazole derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



— Et

L17 ANSWER 30 OF 41 USPATFULL on STN
 ACCESSION NUMBER: 2005:30296 USPATFULL
 TITLE: Cosmetic or dermatological light-protective formulation comprising a benzotriazole and a benzoxazole derivative
 INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF Groteluschen, Birgit, Wildeshausen, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2005025726 | A1 | 20050203 |
| | US 7029660 | B2 | 20060418 |
| APPLICATION INFO.: | US 2004-871839 | A1 | 20040618 (10) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 2002-EP14392, filed on 17 Dec 2002, UNKNOWN | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | DE 2001-10162842 | 20011220 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000 | |
| NUMBER OF CLAIMS: | 54 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1897 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation, comprising (a) at least benzotriazole and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one benzotriazole from a select group and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising benzotriazoles and benzoxazole derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)



— Et

L17 ANSWER 31 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:16381 USPATFULL

TITLE: Cosmetic or dermatological light-protective formulation comprising a bisresorcinyl triazine derivative and a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF

Hoop, Kerstin, Pinneberg, GERMANY, FEDERAL REPUBLIC OF Beiersdorf AG (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2005013782 | A1 | 20050120 |
| APPLICATION INFO.: | US 2004-871818 | A1 | 20040618 (10) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 2002-EP14297, filed on 16 Dec 2002, UNKNOWN | | |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | DE 2001-10162844 | 20011220 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000 | |
| NUMBER OF CLAIMS: | 64 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1838 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a cosmetic or dermatological preparation effective as light-protective, comprising (a) at least one bis-resorcinyltriazine derivative and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one bis-resorcinyltriazine derivative and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising
derivs. of bis-resorcinyl triazine derivs. and benzoxazole)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-
benzoxazolyl]phenyl]-N'''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 32 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:120834 USPATFULL

TITLE: Protective method

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Fankhauser, Peter, Ettingen, Switzerland
Eckhardt, Claude, Riedisheim, France

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

| NUMBER | KIND | DATE |
|--------|------|------|
|--------|------|------|

| | | |
|---------------------|----------------|--------------|
| PATENT INFORMATION: | US 6117189 | 20000912 |
| APPLICATION INFO.: | US 1995-438591 | 19950510 (8) |

| NUMBER | DATE |
|--------|------|
|--------|------|

| | | |
|-----------------------|--------------|----------|
| PRIORITY INFORMATION: | GB 1994-9465 | 19940512 |
|-----------------------|--------------|----------|

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Diamond, Alan

LEGAL REPRESENTATIVE: Mansfield, Kevin T.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the improvement of the sun protection factor (SPF) of textile fiber material, comprising applying to the textile fiber material a detergent comprising at least one fluorescent whitening agent, which absorbs radiation in the wavelength

range 280-400 nm, preferably by washing the textile fiber material with a detergent containing said fluorescent whitening agent.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6

(fluorescent whitener, detergent component; textile finishing for sun protection)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyil)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L17 ANSWER 33 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:80216 USPATFULL

TITLE: Stilbene compounds and their use

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of

Metzger, Georges, Moernach, France

Sauter, Hanspeter, Schopfheim, Germany, Federal
Republic of

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6080208 20000627

APPLICATION INFO.: US 1998-218246 19981222 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-862036, filed on 22 May
1997, now patented, Pat. No. US 5892031

NUMBER DATE

PRIORITY INFORMATION: GB 1996-10832 19960523

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Gupta, Yogendra

ASSISTANT EXAMINER: Mruk, Brian P.

LEGAL REPRESENTATIVE: Mansfield, Kevin T.

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

LINE COUNT: 717

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides new stilbene compounds which are useful as fluorescent whitening agents (FWAs), imparting high whiteness levels to textile fibre material treated with them, and which also impart a high sun protection factor (SPF) to textile fibre material treated with them. The present invention also concerns a method of imparting a high whiteness level and a high sun protection factor to textile fibre material, especially cotton, polyamide and wool, comprising treating the textile material with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 199791-75-8P

(manufacture and use of stilbene compds. as fluorescent whitening agents and UV absorbers)

RN 199791-75-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[(acetylamino)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]--, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na

PAGE 1-B



L17 ANSWER 34 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:102785 USPATFULL

TITLE: Compounds

INVENTOR(S): Eckhardt, Claude, Riedisheim, France
Metzger, Georges, Moernach, France
Reinehr, Dieter, Kandern, Germany, Federal Republic of
Sauter, Hanspeter, Schopfheim, Germany, Federal
Republic of
Dubini, Mario, Niederdorf, Switzerland

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5945396 19990831
APPLICATION INFO.: US 1997-996895 19971223 (8)

NUMBER DATE

PRIORITY INFORMATION: GB 1996-26851 19961224

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Green, Anthony

LEGAL REPRESENTATIVE: Mansfield, Kevin T.

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 9

LINE COUNT: 623

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a compound having the formula: ##STR1##

in which each R.sub.d is the same or different and each is --NH--Z--N(R.sub.a)(R.sub.b) or --N--[Z--N(R.sub.a)(R.sub.b)].sub.2 in which Z is C.sub.2 -C.sub.14 alkylene or optionally substituted arylene, R.sub.a and R.sub.b are the same or different and each is C.sub.1 -C.sub.12 alkyl, or R.sub.a and R.sub.b, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; each R.sub.c is the same or different and is NH.sub.2, NH(C.sub.1 -C.sub.4 alkyl), N(C.sub.1 -C.sub.4 alkyl).sub.2, N(CH.sub.2 CH.sub.2 OH).sub.2, O--C.sub.1 -C.sub.4 alkyl, ##STR2## alkali metal atom, ammonium or a cation formed from an amine; or a quaternized form thereof. The present invention also relates to a composition for the treatment of textiles, in particular to a composition containing the new ultra-violet absorbing agents; and to a method for the improvement of both the sun protection factor (UPF) and the whiteness of textile fiber material, comprising treating the material with the composition according to the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 210101-86-3P

(preparation of triazinylaminostilbenes as ultra-violet absorbing agents for textile fibers)

RN 210101-86-3 USPATFULL


CN Benzoic acid, 4,4'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-[[2-(dimethylamino)ethyl]amino]-1,3,5-triazine-4,2-diyl]imino]]bis-, tetrasodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●4 Na

PAGE 1-B



L17 ANSWER 35 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:43769 USPATFULL

TITLE: Stilbene compounds and their use

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Metzger, Georges, Moernach, France
Sauter, Hanspeter, Schopfheim, Germany, Federal
Republic of

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

| NUMBER | KIND | DATE |
|--------|-------|-------|
| ----- | ----- | ----- |

PATENT INFORMATION: US 5892031 19990406
APPLICATION INFO.: US 1997-862036 19970522 (8)

NUMBER DATE

PRIORITY INFORMATION: GB 1996-10832 19960523

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Ford, John M.

LEGAL REPRESENTATIVE: Mansfield, Kevin T.

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

LINE COUNT: 624

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides new stilbene compounds which are useful as fluorescent whitening agents (FWAs), imparting high whiteness levels to textile fibre material treated with them, and which also impart a high sun protection factor (SPF) to textile fibre material treated with them. The present invention also concerns a method of imparting a high whiteness level and a high sun protection factor to textile fibre material, especially cotton, polyamide and wool, comprising treating the textile material with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 199791-75-8P

(manufacture and use of stilbene compds. as fluorescent whitening agents and UV absorbers)

RN 199791-75-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[(acetylamino)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na

PAGE 1-B



L17 ANSWER 36 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:104437 USPATFULL

TITLE: Textile treatment

INVENTOR(S): Kaufmann, Werner, Rheinfelden, Switzerland

Reinehr, Dieter, Kandern, Germany, Federal Republic of
Hilfiker, Rolf, Basel, Switzerland

PATENT ASSIGNEE(S) : Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 5800862 | | 19980901 |
| APPLICATION INFO.: | US 1995-438590 | | 19950510 (8) |

| | NUMBER | DATE |
|-----------------------|---------------------|----------|
| PRIORITY INFORMATION: | GB 1994-9466 | 19940512 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Bell, Janyce | |
| LEGAL REPRESENTATIVE: | Mansfield, Kevin T. | |
| NUMBER OF CLAIMS: | 54 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1059 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a improving the sun protection factor (SPF) of textile fibre material comprising treating the textile fibre material with a composition comprising at least one fluorescent whitening agent which absorbs radiation in the wavelength range 280-400 nm.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6

(fluorescent whitener, detergent component; textile finishing for sun protection)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L17 ANSWER 37 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:82878 USPATFULL

TITLE: Dyestuff mixtures of fiber-reactive azo dyestuffs and their use for dyeing fiber material containing hydroxyl and/or carboxamide groups

INVENTOR(S) : Schumacher, Christian, Kelkheim, Germany, Federal Republic of Russ, Werner Hubert, Florsheim, Germany, Federal Republic of

PATENT ASSIGNEE(S) : Pystar Textilfarben GmbH & Co. KG, Deutschland, Germany, Federal Republic of (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 5780602 | | 19980714 |
| APPLICATION INFO.: | US 1997-924746 | | 19970905 (8) |

| | NUMBER | DATE |
|-----------------------|------------------|----------|
| PRIORITY INFORMATION: | DE 1996-19635999 | 19960905 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Powers, Fiona T. | |
| LEGAL REPRESENTATIVE: | Connolly & Hutz | |
| NUMBER OF CLAIMS: | 21 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 957 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mixtures of fiber-reactive azo dyestuffs with which black dyeings, including prints, are obtained on fiber materials containing hydroxy and/or carboxamide groups, such as cellulosic fiber materials, wool and synthetic polyamide fibers, are described. These dyestuffs mixtures comprise one or more dyestuffs of the following formulae (1) and (2): ##STR1## in which the substituents have the meaning given in the specification.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183205-49-4

(mixts. of fiber-reactive azo dyes and their use for dyeing hydroxy and/or carboxamide group-containing fibers)

RN 183205-49-4 USPATFULL

CN Benzenesulfonic acid, 2-amino-4-[[4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]aminol-5-[[4-[[2-(sulfoxyethyl)sulfonyl]phenyl]azo]-, trisodium salt (9CI) (CA INDEX NAME)



● 3 Na

L17 ANSWER 38 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:82064 USPATFULL

TITLE: Dye mixtures of fiber-reactive azo dyes and their use for dyeing hydroxy-and/or carboxamido-containing fiber material

INVENTOR(S): Von Der Eltz, Andreas, Frankfurt am Main, Germany,
Federal Republic of
Russ, Werner Hubert, Florsheim, Germany, Federal
Republic of
Grobel, Bengt-Thomas, Niederems, Germany, Federal
Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Germany, Federal Republic
of (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 5779739 | | 19980714 |
| APPLICATION INFO.: | US 1996-627937 | | 19960328 (8) |

| | NUMBER | DATE |
|--|--|----------|
| PRIORITY INFORMATION: | DE 1995-19511688 | 19950330 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Einsmann, Margaret | |
| LEGAL REPRESENTATIVE: | Connolly and Hutz | |
| NUMBER OF CLAIMS: | 18 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 1 Drawing Figure(s); 1 Drawing Page(s) | |
| LINE COUNT: | 975 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

AB Dye mixtures of fiber-reactive azo

AB Bye mixtures of fiber-reactive azo dyes and their use for dyeing hydroxy- and/or carboxamido-containing fiber material

Red-dyeing fiber-reactive phenylazoaminonaphthol dyes, yellow-dyeing fiber-reactive phenylazoaminobenzene dyes, blue-dyeing fiber-reactive copper formazan dyes and navy-dyeing fiber-reactive disazo dyes of the formulae (1) to (5) as claimed and defined in claim 1 are described which are suitable for dyeing hydroxy- and/or carboxamido-containing fiber material, such as cellulose fiber materials, wool and synthetic polyamide fibers individually or together or some of them together or as a mixture in trichromatic dyeing methods. During the dyeing process a definite hue within the color triangle can be obtained and kept constant by adding the individual dye solutions of the individual dyes and/or mixtures of some of the dyes in a controlled manner by means of the ATR measurement technique.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183205-49-4

(mixts. of reactive azo dyes for trichrome dyeing of fibers containing hydroxy and/or carbonamide functional groups)

RN 183205-49-4 USPATFULL

CN Benzenesulfonic acid, 2-amino-4-[(4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-[(4-[2-(sulfoxy)ethyl]sulfonyl)phenyl]azo]-, trisodium salt (9CI) (CA INDEX NAME)



● 3 Na

ACCESSION NUMBER: 97:109269 USPATFULL
 TITLE: Black dye mixtures of fiber-reactive azo dyes and their use for dyeing hydroxyl- and/or carboxamido-containing fiber material
 INVENTOR(S): Von Der Eltz, Andreas, Frankfurt am Main, Germany, Federal Republic of
 Russ, Werner Hubert, Florsheim, Germany, Federal Republic of
 Buchwald, Dirk, Selters, Germany, Federal Republic of
 Hoechst Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 5690698 | | 19971125 |
| APPLICATION INFO.: | US 1996-611630 | | 19960306 (8) |

| | NUMBER | DATE |
|-----------------------|--------------------|----------|
| PRIORITY INFORMATION: | DE 1995-19508156 | 19950308 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Einsmann, Margaret | |
| LEGAL REPRESENTATIVE: | Connolly and Hutz | |
| NUMBER OF CLAIMS: | 11 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 551 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dye mixture of azo dyes having fiber-reactive groups of the vinylsulfone series, comprising one or more navy-blue disazo dyes with the bivalent 1-amino-8-hydroxy-3,6-disulfo-naphthylene coupling component, one or more red-dyeing mono azo dyes, containing a phenylamino-chlorotriazinylamino-disulfo-naphthol-coupling component and one or more orange-dyeing monoazo dyestuffs with an amino-sulfonaphthol-coupling component, which dye mixtures are suitable for dyeing hydroxyl- and/or carboxamido-groups containing materials, in particular fiber materials, such as cellulose fibers, for example cotton, wool and synthetic polyamide fibers.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 156291-01-9

(dyes containing; black dye mixts. of reactive azo dyes for dyeing of hydroxyl- and/or carbonamide group-containing fibers)

RN 156291-01-9 USPATFULL

CN Benzenesulfonic acid, 2-amino-4-[[4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-(9CI) (CA INDEX NAME)



L17 ANSWER 40 OF 41 USPATFULL on STN
ACCESSION NUMBER: 97:107045 USPATFULL
TITLE: Textile treatment
INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Eckhardt, Claude, Riedisheim, France
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 5688758 | | 19971118 |
| APPLICATION INFO.: | US 1996-662091 | | 19960612 (8) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1995-471043, filed on 6 Jun 1995, now abandoned | | |


| | NUMBER | DATE |
|-----------------------|---------------------|----------|
| PRIORITY INFORMATION: | GB 1994-13270 | 19940701 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Green, Anthony | |
| LEGAL REPRESENTATIVE: | Mansfield, Kevin T. | |
| NUMBER OF CLAIMS: | 27 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 790 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a stable, concentrated fabric rinse composition comprising 0.3 to 10, preferably 0.3 to 3% by weight of a fluorescent whitening agent which is compatible with a fabric care ingredient, preferably a cationic, amphoteric or anionic fluorescent whitening agent, based on the total weight of the composition, and optionally a fabric care ingredient, preferably a fabric softener, a stain release or stain repellent ingredient or a water-proofing agent, the remainder being substantially water. The fabric rinse composition is preferably a fabric softener composition comprising 5 to 25, preferably 10 to 20% by weight of a cationic fabric softening agent and 0.3 to 10, preferably 0.3 to 3% by weight of a cationic, amphoteric or anionic fluorescent whitening agent, each based on the total weight of the composition, the remainder being substantially water. The present invention also provides method for the treatment of a textile article, comprising applying, to the previously washed article, the said fabric rinse composition, preferably the rinse cycle fabric softener composition, whereby the sun protection factor, and other properties such as the tear Strength and lightfastness of articles so treated can be significantly increased.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6
(fluorescent whitener, detergent component; textile finishing for sun protection)
RN 31900-04-6 USPATFULL
CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

L17 ANSWER 41 OF 41 USPATFULL on STN

ACCESSION NUMBER: 83:41227 USPATFULL

TITLE: Method for immunochemical measurement of trace components

INVENTOR(S): Masuda, Nobuhito, Minami-ashigara, Japan
Nagatomo, Shigeru, Minami-ashigara, Japan

PATENT ASSIGNEE(S): Mihara, Yuji, Minami-ashigara, Japan
Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 4404289 | | 19830913 |
| APPLICATION INFO.: | US 1981-298719 | | 19810902 (6) |

| | NUMBER | DATE |
|-----------------------|--|----------|
| PRIORITY INFORMATION: | JP 1980-120597 | 19800902 |
| | JP 1980-120598 | 19800902 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Marantz, Sidney | |
| LEGAL REPRESENTATIVE: | Sughrue, Mion, Zinn, Macpeak, and Seas | |
| NUMBER OF CLAIMS: | 8 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1619 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In an immunochemical measurement method of an antigen or antibody which comprises competitively reacting an antigen or antibody labelled with spectral sensitizer and an antigen or antibody to be measured, bringing either the reaction product of immune reaction or the unreacted component into contact with silver halide, exposing the same to light having a wavelength which the spectral sensitizer absorbs, developing the exposed silver, and, measuring optical density of the thus formed silver image and/or colored dye, the contact with silver halide is performed in the presence of a specific hydrazine compound. Thus, detection sensitivity is markedly improved.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 28837-51-6
(stabilizer, in immunoassay with photochem. detection)

RN 28837-51-6 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(2-naphthalenylamino)-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI)
(CA INDEX NAME)

PAGE 1-A



●2 Na

PAGE 1-B



> file caplus medline 119
'L19' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> file caplus medline

COST IN U.S. DOLLARS

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
|------------------|---------------|

FULL ESTIMATED COST

166.94

1350.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
|------------------|---------------|

CA SUBSCRIBER PRICE

0.00

-24.75

FILE 'CAPLUS' ENTERED AT 16:38:35 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:38:35 ON 20 DEC 2006

=> s 119

L20 208 L19

=> s 120 and (cancer or tumour or tumor or carcinoma or neoplas? or chemo? or cancer?)

L21 0 L20 AND (CANCER OR TUMOUR OR TUMOR OR CARCINOMA OR NEOPLAS? OR CHEMO? OR CANCER?)

=> s 120 and (edg or lpa or lysophosphatidic acid)

L22 0 L20 AND (EDG OR LPA OR LYSOPHOSPHATIDIC ACID)

=> s 120 and (ov202 or htc or caov or mda-mb or ht-1080 or huvec or a431 or hamster or ovary or ovarian or hepatoma or breast)

L23 0 L20 AND (OV202 OR HTC OR CAOV OR MDA-MB OR HT-1080 OR HUVEC OR A431 OR HAMSTER OR OVARY OR OVARIAN OR HEPATOMA OR BREAST)

=> file caplus uspatful

COST IN U.S. DOLLARS

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
|------------------|---------------|

FULL ESTIMATED COST

59.95

1410.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
|------------------|---------------|

CA SUBSCRIBER PRICE

0.00

-24.75

FILE 'CAPLUS' ENTERED AT 16:41:03 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:41:03 ON 20 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 119

L24 377 L19

=> s 124 and (ov202 or htc or caov or mda-mb or ht-1080 or huvec or a431 or hamster or ovary or ovarian or hepatoma or breast)

L25 0 L24 AND (OV202 OR HTC OR CAOV OR MDA-MB OR HT-1080 OR HUVEC OR A431 OR HAMSTER OR OVARY OR OVARIAN OR HEPATOMA OR BREAST)